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Unraveling How Dysfunction of the Microglial Gene TREM2 Increases Risk 
for Alzheimer’s Disease 
Faten Sayed 
Abstract 
 
 A heterozygous single amino acid change in the TREM2 gene significantly increases risk 
for developing late-onset Alzheimer’s Disease (AD). In the brain, Trem2 is uniquely expressed 
by microglia, strongly implicating microglia in AD pathogenesis. Trem2 is a receptor with 
numerous ligands and pleiotropic functions ranging from phagocytosis to inflammation and 
synapse pruning. There has been a significant amount of research on the consequences of 
Trem2 deficiency in amyloid mouse models. Trem2-deficient mice exhibit reduced microglial 
clustering around amyloid-beta plaques and reduced levels of inflammatory transcripts. The 
consequence of Trem2 deficiency in the context of tau pathology, on the other hand, is not well 
understood. To address this gap, we investigated the effects of Trem2 haploinsufficiency and 
deficiency on microglial function in the healthy brain and in the context of tauopathy. We found 
that removing one copy of Trem2 significantly impaired microglia’s ability to respond to injury in 
vivo to a greater extent than removing both copies of Trem2. Moreover, Trem2 haploinsufficient 
mice exhibited an increase in tau load, whereas tau load in Trem2 deficient mice was 
unimpacted or slightly reduced. The increase in tau load in Trem2 haploinsufficient mice 
correlated with increased levels of pro-inflammatory transcripts and neurodegeneration. Trem2 
deficient mice, on the other hand, exhibited reduced levels of pro-inflammatory transcripts and 
less neurodegeneration. To determine how a single amino acid change in TREM2 increases risk 
for AD, we used CRISPR to generate two novel mouse models expressing one copy of wild-
type or R47H human TREM2 (R47H-hTREM2) driven by the endogenous mouse Trem2 
promoter. We found that R47H-hTREM2 caused aberrant hippocampal synaptic transmission 
	 xi	
and impaired spatial memory. In the context of tauopathy, it exacerbated spatial learning and 
memory as well, and resulted in higher levels of pro-inflammatory and disease-associated 
microglial transcripts. Moreover, R47H-hTREM2 microglia caused transcriptional changes in 
neurons and oligodendrocytes, pertaining to metabolism and oxidative phosphorylation. Lastly, 
there was significant overlap between our R47H-hTREM2 mouse model and AD patients with 
the R47H mutation. The most significant overlap was in oligodendrocyte transcripts related to 
mitochondrial dysfunction and oxidative phosphorylation. In sum, the work highlighted in this 
dissertation highlights how losing one copy of a gene can be more detrimental than losing both 
copies and how a single amino acid change in one cell type in the brain can have widespread 
non-cell autonomous ramifications resulting in cognitive deficits. Hopefully, the pathways 
highlighted in this work can help guide the development of therapeutic strategies targeted at 
microglial dysfunction in AD.  
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Chapter 1: Introduction 
 
1.1 Human Genetics Studies Implicate Microglia in Alzheimer’s Disease Pathogenesis  
 
Alzheimer’s disease (AD) is the most common form of dementia in elderly patients. 5.8 
million Americans are currently suffering from the disease and every 65 seconds, someone in 
the United States develops AD1. It is currently the 6th leading cause of death in the U.S. and 
costs the nation $290 billion, most of which is due to the billions of hours that caregivers work to 
take care of seniors with AD1. Given these alarming facts, it is critical to identify therapeutics 
that slow or even halt disease progression.  
Alzheimer’s disease is a neurodegenerative disorder identified neuropathologically by 
the presence of two abnormal protein aggregates: extracellular amyloid-beta plaques and 
intraneuronal tau tangles. In addition, AD is also characterized by increased activation of 
microglia, the immune cells in the brain2. This aberrant microglial phenotype was largely 
considered a response to the buildup of protein aggregates, and not a cause of disease. 
However, recent human genetics studies have shifted the paradigm in the field, highlighting 
microglia as causal factors in pathology. 
 Microglia, as the brain’s immune cells, are tasked with constantly surveying the brain3,4 
for damage or pathogens. They are phagocytic, eliminating debris and under-utilized synapses5-
9. Unlike other brain cells which arise from neuroepithelial progenitors, microglia come from 
hematopoietic stem cells in the primitive yolk sac10,11 and replenish their numbers through self-
renewal12, as opposed to other myeloid cells which are renewed by monocytes circulating in the 
blood.  
In AD brain tissue, microglia are found surrounding amyloid-beta plaques. Their 
proximity to the plaques led to the hypothesis that microglia are clearing up the aggregates and 
limiting their spread. Indeed, portions of the plaques that are not covered by microglial 
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processes are less compact and are associated with greater axonal dystrophy13. While this 
suggests that microglia are attempting to protect the brain, recent genome-wide association 
studies have identified numerous microglial genes that, when mutated, increase risk for late-
onset AD (LOAD)14-18. These findings move microglia from the sidelines into the spotlight, as 
they suggest that aberrant microglial function can increase susceptibility to disease, and even 
contribute to AD pathogenesis. 
 
1.2 Trem2 Expression Pattern and Localization in the Brain   
 
While ~1-5% of patients develop early-onset AD due to mutations in the genes APP, 
PSEN1, and PSEN2, the majority of AD patients develop sporadic, late-onset AD. The strongest 
and most common genetic risk factor is the E4 allele of apolipoprotein E (ApoE4), with an odds 
ratio of 3-419,20. Aside from ApoE4, which was identified back in 1993, the field lacked strong 
genetic handles on the disease – until 2013. In 2013, researchers identified the strongest 
immune gene risk factor to date: TREM217,18. A heterozygous single amino acid change from an 
arginine to a histidine at position 47 (R47H) is associated with a 2-4-fold increase in risk for 
developing late-onset AD17,18,21. This increase in risk is comparable to that of ApoE4 
heterozygosity. While the R47H-TREM2 variant is incredibly rare, its high odds ratio suggests 
that it regulates microglial functions that may be key to unlocking microglia’s role in disease 
pathogenesis.  
Triggering receptor expressed on myeloid cells-2 (Trem2) is a single-transmembrane 
receptor, consisting of a signal peptide (residues 1-18), an ectodomain that can be cleaved and 
shed from the cell surface as soluble TREM2 (sTrem2) (residues 19-174), a transmembrane 
domain (residues 175-195), and a short, cytoplasmic tail (residues 196-23). It requires an 
adaptor protein, DNAX-activating protein of 12 kilodaltons (Dap12), to stabilize Trem2 on the 
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cell surface and initiate a signaling cascade22. Trem2 was initially discovered through a screen 
for receptors that would induce cell surface expression of Dap12 on macrophages23.   
Trem2 is only found on cells from the myeloid lineage. In the periphery, Trem2 is 
expressed by osteoclasts, dendritic cells and macrophages24. TREM2 expression was found on 
macrophages infiltrating tissue, but not on peripheral blood cells or bone marrow cells, 
suggesting that its expression may be stimulated by cytokines or by the transition from the 
periphery into tissues25. In the brain parenchyma, Trem2 expression is restricted to microglia26-
29. Of note, baseline Trem2 protein expression in the healthy brain appears to be quite low. 
Trem2 expression was undetectable using immunohistochemistry in adult mouse tissue30. Using 
a Trem2-GFP reporter mouse, it was found that only 5.8% of cortical microglia and 8.7% of 
hippocampal microglia expressed Trem231. On the other hand, 95-97% of microglia are positive 
for Trem2 when stained in culture or sorted using fluorescence-activated cell sorting 
(FACS)26,27, suggesting that stressful conditions that activate microglia, such as being cultured 
or sorted, can increase Trem2 levels. While Trem2 expression has been found on neurons in 
both mouse and human tissue32, it is now believed that this is due to sTrem2 binding to 
neurons33, and not due to neuronal production of Trem2. The nuclei of Trem2+ neurons do not 
appear pyknotic or fragmented33, suggesting that sTrem2 binds to healthy neurons. Moreover, 
neuronal sTrem2 staining is very minimal in healthy mice, but increases significantly in amyloid 
mouse models33. Its function in neurons remains unknown. In sum, Trem2 mRNA and protein 
are restricted to microglia in the healthy mouse brain, albeit at low levels, and Trem2 
ectodomain staining is also found on neurons in an AD mouse model. Trem2 expression is 
context-specific, increasing under stressful conditions or after cells infiltrate tissue. 
Trem2 mRNA may be differentially expressed across brain regions. In healthy human 
brain tissue, Trem2 mRNA is higher in white matter than in gray matter, and high expression 
levels can be found in the corpus callosum, medulla, hippocampus, thalamus, and basal 
ganglia24,34. In the healthy mouse brain, Trem2 expression appears to be developmentally-
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regulated. The highest expression occurs early on and by postnatal day 10, staining for Trem2 
can only be found in the corpus callosum35. However, western blot of 6-week-old mice identified 
high Trem2 protein levels in the hippocampus32, suggesting that staining may not be sensitive 
enough to detect the already low levels of Trem2 in the healthy brain. Overall, these studies 
suggest that Trem2 expression is not uniformly distributed across the brain, with highest 
expression in the white matter over the gray matter, and more specifically, in the corpus 
callosum, basal ganglia, hippocampus, medulla and thalamus.  
 
1.3 Trem2 Exhibits Pleiotropic Functions in the Healthy Brain 
 
Trem2 binds numerous ligands: bacteria, lipids, healthy and apoptotic neurons, anionic 
ligands, apolipoproteins, and amyloid-beta26,33,36-45. Its in vivo ligands remain unknown, though 
Apoe may be one of them. Out of its numerous ligands, its role as a lipid sensor has taken 
center stage in AD research due to the accumulation of lipids around plaques. Trem2 signaling 
is stimulated by negatively charged phospholipids that associate with amyloid-beta plaques, 
membrane phospholipids exposed by dying neurons, and anionic non-phosphate lipids released 
by damaged myelin41,45, all of which are found in disease states.  
Alongside its role as a lipid sensor, Trem2 also promotes microglial chemotaxis46-48. 
Stimulation of Trem2 in primary microglia promotes their migration towards chemokines, and 
Trem2 deficiency impairs microglia’s ability to migrate toward dying tissue in vitro and in vivo46-
48. It is hypothesized that Trem2 binds lipids and signals to microglia to move towards the lipid-
dense region, such as an amyloid plaque. Indeed, Trem2-deficient microglia show impaired 
migration towards amyloid-beta in vitro44. 
 Trem2 is a phagocytic receptor. Expression of Trem2 is sufficient to induce 
phagocytosis in non-phagocytic cells, such as Chinese Hamster Ovary cells49. Trem2 
stimulation increases F-actin levels, a critical part of the phagocytic process, and promotes 
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phagocytosis of apoptotic neurons by primary microglia27. However, loss of Trem2 does not 
always impair phagocytosis. In the absence of any other mutation, Trem2 knockout primary 
microglia phagocytose amyloid-beta normally50. When amyloid-beta is lipidated, though, Trem2-
knockout primary microglia exhibit impaired uptake and degradation42, indicating that Trem2 
may be especially critical for lipid-related phagocytosis. Moreover, when microglia are activated, 
such as in an amyloid mouse model, Trem2 may not be necessary for phagocytosis. Trem2 
knockdown reduces phagocytosis of apoptotic neurons in primary microglia27. However, Trem2 
knockout microglia from an amyloid mouse model phagocytosed apoptotic cells just as well as 
Trem2 wild-type microglia from the same amyloid mouse model41. These contradictory findings 
suggest that in highly activated microglia, such as in the context of amyloid pathology, other 
phagocytic receptors may be upregulated and able to compensate for the lack of Trem2. In 
sum, while stimulation of Trem2 promotes phagocytosis, and expression of Trem2 is sufficient 
to confer phagocytic capability, Trem2 may not be required for phagocytosis, particularly when 
microglia are activated.  
In addition to promoting phagocytosis, Trem2 also promotes proliferation41,45,51-53. 
Microglia are highly proliferative cells, increasing in number during disease states and during 
aging54. Trem2 knockout and Trem2 wild-type microglia start off at similar densities in the 
mouse brain at 0.5 years of age. In wild-type mice, the number of microglia doubles by 2 years 
of age. In Trem2 knockout mice, though, the number of microglia stays the same from 0.5-2 
years of age, suggesting impaired proliferation45. A similar phenomenon of blunted proliferation 
with age is seen in Trem2-deficient microglia in an amyloid mouse model55. Indeed, there are 
fewer BrdU+ microglia in Trem2-knockout mice, further indicating impaired proliferation52. 
In addition to age, Trem2 knockout microglia also show a blunted response to other 
challenges, such as treatment with cuprizone or kainic acid. Cuprizone is a copper-chelating 
agent that produces demyelination in the brain. During treatment with cuprizone, wild-type 
microglia quadruple in number, then return to baseline numbers during recovery. Trem2 
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knockout microglia, on the other hand, only double in number and stay at that level even during 
recovery45. Trem2 knockout microglia also exhibit blunted proliferation in response to kainic 
acid, which induces excitotoxity and neuronal death56. In sum, Trem2 promotes microglial 
proliferation in response to stimuli. In its absence, microglia proliferate less, which may impede 
recovery from the challenge.   
Trem2’s role in cell proliferation may be mediated, in part, by regulation of the Wnt 
signaling pathway. The majority of Trem2-deficient microglia are in the G0/G1 phase of the cell 
cycle, with few microglia in S phase, suggesting cell cycle arrest52. Trem2 is thought to promote 
survival by stabilizing ß-catenin, a key part of the Wnt signaling pathway52. However, Wnt 
activation does not fully rescue the proliferation deficits seen in Trem2 knockout microglia52, 
suggesting that there are other pathways at play that remain to be identified. 
In addition to promoting cell proliferation, Trem2 also stimulates cell survival. Trem2 
knockout plaque-associated microglia have increased TUNEL staining compared to Trem2 wild-
type microglia surrounding plaques, suggesting increased apoptosis41,55. A key regulator of 
microglia survival is the CSF1 ligand secreted by neurons, which binds to CSF1R on 
microglia57. Trem2 promotes microglial survival under conditions of limited CSF1; in Trem2’s 
absence, microglia viability is severely reduced41. One hypothesis in the field is that CSF1 levels 
may be limited in plaque-dense areas, thus making Trem2-deficient microglia less fit to survive 
and consequently, less able to respond to the injury.  
Trem2 was recently implicated in developmental synapse pruning. Neurons from Trem2-
deficient mice (aged postnatal day 18-20) exhibit an increase in miniature excitatory 
postsynaptic current (mEPSC) frequency in the hippocampus, and an increased density of 
synaptic markers PSD95 and VGLUT158. This was due to a non-cell autonomous effect of 
Trem2-deficient microglia on neurons, as wild-type neurons co-cultured with Trem2 knockout 
microglia also show aberrant synaptic transmission, while synaptic transmission is normal in 
Trem2 deficient neurons. However, in slightly older (1-month-old) mice, Trem2-deficiency 
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results in a reduction in mEPSC frequency and PSD95 levels in the same region of the 
hippocampus59. It is possible that Trem2’s effect on synaptic transmission is age-dependent. 
However, aged Trem2-deficient mice exhibit an increase in PSD9560, similar to the findings in 
mice aged postnatal day 18-20. While these studies indicate that Trem2 can regulate synapse 
pruning, future studies are needed to determine how it regulates synapse pruning throughout a 
mouse’s lifetime. 
Trem2 has been implicated as a regulator of inflammation, albeit with conflicting results. 
Classically, Trem2 in the periphery is considered anti-inflammatory, as stimulating Trem2 
macrophages in vitro increases levels of anti-inflammatory transcripts25. However, in vivo in the 
brain, Trem2 may be pro-inflammatory, as Trem2 knockout mice express reduced levels of pro-
inflammatory cytokines in the aging brain and in amyloid and tau mouse models46,55,60,61. In vivo, 
Trem2 may be needed to promote microgliosis, or the activated state of microglia, in response 
to a stimulus. Through RNA-sequencing, multiple studies have found that Trem2-deficient 
microglia fail to mount the typical pro-inflammatory response to amyloid pathology, and instead 
seem frozen in a homeostatic state41,47,62. Indeed, this dichotomy between in vivo versus in vitro 
effects of Trem2 on inflammation can be seen in one study by Wang et al. In vitro, Trem2 
knockout primary microglia exhibited increased levels of pro-inflammatory transcripts in 
response to lipopolysaccharide, suggesting that Trem2 is anti-inflammatory. However, in vivo in 
an amyloid mouse model, Trem2-deficient microglia’s transcriptome resembled that of non-
transgenic microglia, suggesting that Trem2 is pro-inflammatory41. The reason behind this 
context-dependent effect of Trem2 on inflammation remains unknown. 
 
1.4 Complex Effects of Trem2 Deficiency in the Context of Amyloid Pathology 
 
 Trem2 mutations have been implicated in several neurodegenerative disorders63-66. Loss 
of Trem2 function causes Nasu-Hakola disease, a rare pre-senile dementia associated with 
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bone cysts34. Interestingly, the corpus callosum and basal ganglia are especially impacted in 
these patients67, which may be related to Trem2’s high expression levels in these two brain 
regions24,34. These patients also exhibit demyelination, axon loss, cerebral atrophy and 
microgliosis – predominantly in the white matter34,67. These patients do not have any 
intraneuronal or glial inclusions, but do exhibit white matter lesions67, which has led to a theory 
of failed lipid metabolism underpinning this symptom68. Interestingly, 2-year-old Trem2 knockout 
mice do not show any hallmarks of Nasu-Hakola disease45, indicating that knocking out Trem2 
in mice is not sufficient to induce this disease as it is in humans.  
 Based on Trem2’s causal role in Nasu-Hakola disease, pioneering work on Trem2 in the 
mouse brain started with demyelination experiments. Cuprizone treatment results in similar 
levels of demyelination in Trem2 wild-type and knockout mice 4 weeks into treatment. However, 
12 weeks into treatment, the corpus callosum of wild-type mice started showing signs of 
remyelination, while the corpus callosum in Trem2 knockout mice remained largely 
demyelinated45. This suggests that while Trem2 does not impact initial demyelination, it may 
play a role in remyelination. Indeed, as noted previously, microglia from Trem2-deficient mice 
are unable to proliferate to the same extent as wild-type microglia, which may limit their ability to 
respond to the challenge and clean up myelin debris to allow for remyelination. This phenotype 
of prolonged demyelination led to the hypothesis of Trem2 as a lipid sensor, which has now 
been validated by multiple labs. 
 Since 2013 when Trem2 was identified as a strong risk factor for AD, numerous mouse 
studies have investigated Trem2’s role in amyloid pathology. There have been two reproducible 
finding across mouse models and across different ages of mice: (1) reduced clustering and 
proliferation of microglia around plaques, which is seen in both Trem2 haploinsufficient and 
Trem2 deficient mice30,41,55,69,70 and (2) reduced intensity of Iba1 (a microglial marker) in Trem2 
deficient mice41,46,61. 
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The reduction in microglial clustering around plaques is observed early on, at 4 months 
of age in the 5xFAD amyloid mouse model55. While overall microglia number is no different 
between wild-type and Trem2-deficient mice, Trem2-deficient microglia exhibit reduced Ki67+ 
staining and increased TUNEL staining and around plaques, suggesting impaired proliferation 
and increased apoptosis, respectively41,55,70. One theory behind the reduction in plaque-
associated microglia in Trem2 knockout mice pertains to CSF1R signaling. As mentioned 
previously, CSF1 levels may be limited around plaques. Since Trem2 signaling is necessary for 
survival under low CSF1 conditions41, Trem2-deficient microglia may be less able to survive, let 
alone proliferate, around plaques.  
Trem2-deficient mice also show an increase in plaque area that is not covered by 
microglial processes70. Notably, the reduction in the number of microglia around plaques is not 
large enough to explain this reduction in plaque surface coverage by microglial processes70. 
Upon closer inspection, Trem2-deficient microglial processes appear to have more loops, 
instead of being fully extended around plaques70. This indicates that the reduction in plaque 
coverage may be due to an impairment in Trem2-deficient microglia’s ability to extend their 
processes towards the plaques. Indeed, early work in the field showed that stimulating Trem2 
increases F-actin levels27. In the absence of Trem2, microglia may be less able to mobilize actin 
in order to extend their processes towards the plaques. However, this does not explain why 
Trem2-deficient microglial processes have more loops, which suggests an inability to organize 
microtubules linearly to reach the plaque. 
Oddly, overexpression of Trem2 using a bacterial artificial chromosome (BAC) also 
reduced microglia clustering around plaques31. This surprising finding may suggest that 
microglia are very sensitive to Trem2 levels – too much or too little and they are unable to 
function properly in certain contexts. In sum, Trem2-defiicent microglia around plaques exhibit 
reduced clustering, reduced proliferation and increased apoptosis, potentially due to impaired 
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CSF1-CSF1R signaling. They also have fewer processes covering the plaques, possibly due to 
an impaired ability to recruit actin or organize the microtubules for cytoskeletal rearrangements.   
In addition to impaired proliferation and survival, Trem2-deficient microglia in an amyloid 
mouse model also exhibit increased autophagy71. Importantly, this is also true for human AD 
patients with TREM2 risk variants71. Autophagy typically signals an adaptive response to stress 
that occurs when cells are unable to meet an increased demand for energy and protein 
synthesis. Multiple lines of evidence support reduced energetics in Trem2-deficient mice. 
Mammalian target of rapamycin (mTOR) signaling promotes energetic and anabolic 
metabolism, cell growth and proliferation. In an amyloid mouse model, Trem2-deficient mice 
exhibit reduced mTOR activation71, suggesting reduced energetics. Secondly, Trem2-deficient 
mice demonstrate increased catabolism and reduced ATP levels under low CSF1 conditions71. 
Lastly, they have reduced mitochondrial mass71. Whether the deficiency in mTOR signaling, 
reduced mitochondrial mass, and low levels of ATP all occur prior to the increase in the number 
of autophagic vesicles is unclear. However, treatment with cyclocreatine, a creatine analog that 
can generate a long-acting phosphagen to sustain ATP levels during high energy demands, 
reduced the number of autophagic vesicles in microglia and dystrophic neurites around plaques, 
doubles microglial density around plaques, and reduces apoptotic markers in microglia71. This 
suggests that correcting the metabolic deficiency in Trem2 knockout mice can rescue certain 
pathological phenotypes. The authors hypothesize that Trem2-deficient microglia under stress 
upregulate apoptotic markers because they lack Trem2-dependent survival signals that typically 
compensate for the stressed state. Trem2 may be pivotal for microglial functioning by helping to 
prevent a dysfunctional, low-energy state brought on by disease or stress.  
In addition to impaired microglial clustering around plaques in Trem2-deficent mice, the 
other reproducible finding in the field is reduced Iba1 intensity.  The reduction in Iba1 intensity in 
Trem2-deficient mice suggests reduced microglial activation. Indeed, RNA-sequencing studies 
have reproducibly found that loss of Trem2 in amyloid mouse models shifts the microglial 
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transcriptome towards that of purely wild-type microglia. Trem2 deficiency reduces expression 
of pro-inflammatory transcripts and increases expression of homeostatic transcripts41,47,62,72. 
These results suggest that Trem2 is required for microglial activation; in its absence, microglia 
are trapped in a homeostatic transcriptional state.  
While it is evident that Trem2 regulates microglial proliferation, survival, and 
inflammatory state, Trem2’s effect on amyloid plaque load remains under debate. Some studies 
find that Trem2 deficiency reduces plaque load30,55, while others have noticed an increase in 
plaque load41,51, or no difference in total plaque load69. These contradictory findings may be due 
to differential effects of Trem2 over the course of the disease. Early on, Trem2 deficiency 
reduces plaque load30,55, while later on in the disease, Trem2 deficiency increases plaque 
load41,51. This hypothesis does not explain one study that found no difference in plaque area at 
early or late stages of disease69, though. 
An alternative, or additional, explanation for the discrepancies may be the type of 
antibody used to label plaques. Trem2 haploinsufficient and Trem2 deficient mice have a 
different proportion of compact versus filamentous plaques70. These different types of plaques 
are labeled with different antibodies or have different appearances when stained with the same 
antibody (such as a dense core versus a diffuse core). A careful profiling of these different types 
of plaques identified that Trem2 deficient mice have more filamentous plaques, and these 
plaques are associated with increased neuritic dystrophy early on, even prior to any differences 
in overall plaque load55,70. This was also observed in human AD patients with the R47H-TREM2 
variant70. These findings indicate that Trem2 may play a role in plaque compaction. Microglia 
are thought to form a physical barrier around plaques, limiting the expansion of the plaques and 
the extent of damage to nearby neurons13. In amyloid mouse models, Trem2 expression is 
polarized, with expression highest on the leading edges of microglial processes that are directly 
contacting plaques70. Thus, Trem2 may promote microglial compaction of plaques into dense 
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cores that are less toxic. Reporting plaque morphology in addition to overall plaque number may 
help disambiguate Trem2’s role in plaque load.  
Overall, these findings show how Trem2’s basic functions regulating microglial survival, 
proliferation, cytoskeletal rearrangements, and inflammatory state go awry in its absence during 
disease. Given Trem2’s pleiotropic beneficial functions, could increasing Trem2 levels in 
amyloid mouse models improve pathology? Overexpression of Trem2 in an aggressive amyloid 
mouse model reduces plaque area and the number of dystrophic neurites31. Surprisingly, it also 
reduces Iba1 intensity and the number of microglia around plaques31. The reasons behind these 
counterintuitive findings remain unknown. Increasing soluble Trem2 levels in the same amyloid 
mouse model is also beneficial. It reduces plaque load and neuritic dystrophy overall, while 
improving long-term potentiation56. It also increases levels of pro-inflammatory transcripts and 
the number of plaque-associated and Ki67+ microglia56. These advantageous effects of sTrem2 
require microglia, as microglia depletion along with sTREM2 treatment does not show these 
benefits, neither does treating primary neuronal cultures directly with sTREM256.  
In sum, Trem2 deficiency increases plaque load in late stages of disease, alters plaque 
morphology from compact to filamentous, increases neuritic dystrophy, reduces inflammation, 
and impairs microglia survival and proliferation. Of note, the bulk of these studies focused on 
complete loss of Trem2, which is causal for Nasu-Hakola disease. It is Trem2 heterozygosity 
that increases risk for AD. The few studies that included Trem2 haploinsufficient mice found that 
they either behaved like wild-type mice, or had an intermediate phenotype between wild-type 
and Trem2-knockout mice41,55,69,73.  
 
1.5 Complex Effects of Trem2 Deficiency in the Context of Tau Pathology 
 
 Alzheimer’s disease consists of both amyloid and tau aggregates. However, only three 
studies to date, including the next chapter of this thesis, have focused on Trem2’s role in 
	 13	
tauopathy. Similar to amyloid pathology, there is also controversy over Trem2’s role in tau 
pathology, which may be attributed to the different mouse models used. One study used a 
mouse model that expresses wild-type human tau and found that Trem2 deficiency worsens tau 
pathology74. Another study that used a mouse model expressing mutant human tau found that 
Trem2 deficiency has no effect on tau pathology, but instead reduces neurodegeneration, 
increases synapse density and reduces gliosis61. Whether these contradictory findings are due 
to the presence of mutant versus wild-type tau, or the different stages at which these mice were 
analyzed is unclear. In the presence of mutant human tau, though, both we and others find that 
Trem2-deficiency is beneficial, unlike its detrimental role in amyloid mouse models. 
 Trem2 is not the first protein to show divergent effects on amyloid and tau pathology. 
Deletion of CX3CR1, the microglial chemokine receptor for CX3CL1, reduces amyloid plaque 
load but exacerbates tau pathology75. These differential effects of microglial proteins on amyloid 
and tau may be because of the temporal differences in when these aggregates manifest: 
amyloid appears early on in the disease, while tau appears later. Thus, microglia’s putative 
beneficial response to amyloid plaques may prime them to be more neurotoxic once tau 
pathology appears. Alternatively, localization of these protein aggregates may explain the 
differential effect of microglia: amyloid plaques are extracellular, while tau is intraneuronal. 
Thus, microglia likely interact with these aggregates using different mechanisms.  Microglial 
inflammation may be helpful in clearing out extracellular aggregates, but toxic when dealing with 
neuronal aggregates. Pro-inflammatory molecules can be neurotoxic, particularly in cases of 
chronic inflammation76. Since Trem2 deficiency reduces inflammation in vivo, this may explain 
why it is beneficial for dealing with intraneuronal tau pathology.  
 As mentioned before, Trem2 haploinsufficiency is associated with increased AD risk. Yet 
no studies thus far have looked at Trem2 haploinsufficiency’s effect on tau pathology. To 
address this gap in the field, we used the mutant tau mouse model (P301S) expressing both, 
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one or no copies of Trem2 and investigated the consequences on microgliosis and tauopathy. 
These findings were published in PNAS in 2018 and can be found in chapter two of this thesis.  
 
1.6 R47H-Trem2 Impairs Ligand Binding  
 
 Thus far, studies have focused on loss of Trem2 to understand its role in microglial 
function in health and disease. However, the heterozygous R47H variant of Trem2 is what 
increases risk for AD17,18. More recently, the field has moved into addressing the consequences 
of this point mutation on Trem2 function. 
 R47 is located on the protein surface in the ligand-binding area of the ectodomain40. 
Overall, in vitro studies find that R47H reduces ligand-binding36,37,40-42,44,77,78. This phenotype is 
unlike mutations causal for Nasu-Hakola Disease, which are found buried within the protein and 
impact protein folding and stability, resulting in reduced protein expression at the cell surface 40. 
Moreover, while Nasu-Hakola disease mutations are unable to bind lipoproteins, R47H still 
exhibits some binding and uptake42. This aligns with the fact that the R47H mutation increases 
risk for AD, while the Nasu-Hakola Disease mutations are causal for disease and therefore are 
expected to have more severe phenotypes. Of note, phosphatidylcholine and sphingomyelin, 
which were found to activate a Trem2 reporter cell line the most effectively out of all lipids 
tested41, still bind to R47H almost as effectively as wild-type Trem241,78. These two lipids may 
have an especially strong affinity for Trem2, such that the mutant form is still able to bind them. 
Or, they may have a different binding pocket in the protein that is not impacted by R47H. Since 
R47H can bind some lipids, it may retain some functionality and is therefore likely only a partial 
loss-of-function mutation.  
Aside from reduced ligand binding, R47H-Trem2 behaves similarly to wild-type Trem2, 
exhibiting weak or no phenotype with respect to impairments in sTrem2 shedding, Trem2 
maturation, and phagocytosis40,50,79. R47H-Trem2 has similar cell surface expression as wild-
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type, it does not accumulate intracellularly in the endoplasmic reticulum like known loss-of-
function Trem2 mutations, and is able to phagocytose bacteria normally (though it is impaired in 
bead phagocytosis, suggesting that its impairments may be substrate-specific)50. There are 
conflicting results regarding its effect on the secretion of soluble Trem2, with one study finding 
reduced secretion50, while another study found no effect on secretion44. Both studies used 
human embryonic kidney cells overexpressing the mutation. The difference in findings may be 
due to culture conditions, i.e. the presence of high levels of CSF1, which can mask the Trem2 
phenotype.  
All the aforementioned studies overexpressed R47H-Trem2 in cell lines, or studied 
recombinant R47H-Trem2. In the human AD, though, patients still have one wild-type copy of 
TREM2. Only one study to date studied heterozygous R47H-Trem2. In vitro, heterozygous 
R47H-Trem2 does not impact macrophage cell survival nor did it induce transcriptomic 
changes, unlike Trem2 deficiency80, suggesting that in the heterozygous condition, one 
functioning copy of Trem2 may be sufficient to induce Trem2 signaling in many cases.  
Several of the in vitro findings align with observations from AD patients with the R47H 
mutation. R47H-carriers have similar levels of TREM2 protein in the brain as AD non-carriers, 
suggesting that TREM2 expression is not impacted by the mutation81. Moreover, the ratio 
between immature non-glycosylated, and mature glycosylated TREM2 is unaffected in R47H-
AD carriers, indicating intact intracellular trafficking of the receptor81. In sum, in humans, R47H-
TREM2 does not impact protein levels or maturation, suggesting that the impairment may occur 
at the levels of ligand-binding and downstream signaling. 
Overall, studies of overexpressed R47H-Trem2 highlight a deficit in ligand binding. 
However, studies of heterozygous R47H-Trem2 have not identified any strong phenotypes that 
could explain its associated risk with AD. One possible explanation for its association with AD 
may be that in the aging, diseased brain, microglia require the maximum amount of Trem2 
signaling. The reduction in signaling caused by only having one fully functioning copy of Trem2 
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and one somewhat impaired copy is significant enough over time to exacerbate disease 
pathogenesis. Studies utilizing endogenously expressed heterozygous R47H-Trem2 are 
required to understand the extent to what the mutation impacts Trem2 signaling, particularly 
over time and after numerous challenges when Trem2 signaling may be especially critical.  
 
1.7 R47h-Trem2 Exhibits Mild Phenotypes in the Context of Amyloid Pathology 
 
In vivo studies have found that R47H results in only a partial loss-of-function, with subtle 
deficits compared to Trem2 deficiency. In vivo, overexpression of R47H-human TREM2 on a 
mouse Trem2 knockout background reduces sTrem2 levels, microgliosis, and microglial 
clustering around plaques33. These phenotypes are similar to what is observed in Trem2-
deficient mice. However, R47H human TREM2 does not affect amyloid beta levels33. Future 
studies are needed to determine whether this variant affects plaque morphology or plaque load 
at different time points. Curiously, R47H human TREM2 mice exhibit significantly reduced 
staining for the extracellular domain of Trem2 on neurons and plaques33. The functional 
consequences of sTrem2 binding to neurons and plaques remain to be determined.  
Another study used CRISPR to knock-in the R47H variant into the mouse Trem2 gene82. 
These mice have fewer microglia around plaques and reduced microglial proliferation. However, 
the mutation also reduced Trem2 levels by 50%, making it a heterozygote. A follow-up study 
discovered that mouse Trem2 has a cryptic splice site that becomes active with the R47H 
variant83. This splice site is not present in humans, though83. This surprising finding suggests 
caution when interpreting results from studies expressing R47H in mouse Trem2, as the 
observed phenotypes may reflect the consequences of Trem2 haploinsufficiency rather than 
that of the mutation. Oddly, though, a contemporary study out of Amgen that also used CRISPR 
to knock-in the R47H variant into the mouse Trem2 gene did not observe any reduction in 
Trem2 mRNA levels in the brain80. One possibility is that the silent mutations they introduced 
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along with the R47H mutation masked the splice site. Further work is needed to resolve these 
conflicting findings.   
These studies are merely the beginnings of the field’s attempt at unraveling the mystery 
behind R47H-TREM2’s pathogenicity. They suggest that R47H-TREM2 results in mild 
phenotypes in the context of amyloid, which aligns with its identification as a risk factor, and not 
a causal factor, for AD. However, given the potential opposing roles of Trem2 on amyloid and 
tau, one major gap in the field is whether R47H-TREM2 is toxic in the context of tau pathology. 
Moreover, no study to date has addressed the functional consequences of the heterozygous 
R47H variant in vivo. To address these gaps, we generated novel wild-type and heterozygous 
R47H human TREM2 knock-in mouse models and crossed them to a tauopathy mouse model 
to determine whether R47H-TREM2 on its own would be pathological, and whether it would 
exacerbate tau pathology. These findings are presented in chapter three of this thesis.    
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Chapter 2: Differential Effects of Trem2 Haploinsufficiency and Deficiency 
on Microglial Function in Health and Disease 
 
2.1 Abstract 
Alzheimer's disease (AD), the most common form of dementia, is characterized by the 
abnormal accumulation of amyloid plaques and hyperphosphorylated tau aggregates, as well as 
microgliosis. Hemizygous missense variants in Triggering Receptor Expressed on Myeloid Cells 
2 (TREM2) are associated with elevated risk for developing late-onset AD. These variants are 
hypothesized to result in loss-of-function, mimicking TREM2 haploinsufficiency. Yet, the 
consequences of TREM2 haploinsufficiency on tau pathology and microglial function remain 
unknown. We report the effects of partial and complete loss of TREM2 on microglial function 
and tau-associated deficits. In vivo imaging revealed that microglia from aged TREM2 
haploinsufficient mice show a greater impairment in their injury response compared to microglia 
from aged TREM2 knockout mice. In transgenic mice expressing mutant human tau, TREM2 
haploinsufficiency, but not complete loss of TREM2, increased tau pathology. In addition, while 
complete TREM2 deficiency protected against tau-mediated microglial activation and atrophy, 
TREM2 haploinsufficiency elevated expression of pro-inflammatory markers and exacerbated 
atrophy at a late stage of disease. The differential effects of partial and complete loss of TREM2 
on microglial function and tau pathology provide important insights into the critical role of 
TREM2 in AD pathogenesis.  
2.2 Significance 
	
Late-onset Alzheimer’s disease is the most common form of dementia. A rare 
hemizygous variant in a microglial-expressed gene, Triggering Receptor Expressed on Myeloid 
Cells 2 (TREM2), significantly increases risk for late-onset Alzheimer’s disease. This variant is 
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thought to cause loss of function, inducing TREM2 haploinsufficiency. The ramifications of 
TREM2 haploinsufficiency on microglial function and tau pathology are major gaps in the field. 
We find that in contrast to the protective effects of complete TREM2 deficiency, TREM2 
haploinsufficiency exacerbates tau pathology, inflammation, and atrophy at a late stage of 
disease in a mouse model of tauopathy. The differential effects of partial and complete loss of 
TREM2 are important considerations for TREM2-targeted therapeutic strategies. 
 
2.3 Introduction 
	
Alzheimer's disease (AD), the most common form of dementia, is characterized 
pathologically by the abnormal accumulation of amyloid plaques, hyperphosphorylated tau 
aggregates, and microgliosis. The recent genetic implication of a microglial-expressed gene, 
Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), in late-onset AD suggests a 
pivotal role for microglia in AD pathogenesis. Although mutations in TREM2 are rare, this gene 
is nonetheless the strongest immune gene-specific risk factor for AD discovered thus far1-3. 
TREM2 encodes a transmembrane receptor that is expressed by microglia in the brain4,5. 
TREM2 has been implicated in neuroinflammation and in the metabolic fitness, proliferation, 
survival, and phagocytic capacity of microglia6-16.  
The most common AD-associated TREM2 variant, R47H, is associated with an 
approximately 3-fold increased risk for developing late-onset AD1-3. It is thought to result in a 
TREM2 loss-of-function phenotype10,17,18. Compared to non-carriers, R47H carriers have higher 
levels of phosphorylated tau around plaques19 and more neurofibrillary tangles20. In addition, 
R47H carriers have higher levels of cerebrospinal fluid (CSF) soluble TREM2, and CSF soluble 
TREM2 levels were significantly correlated with higher levels of CSF phosphorylated tau21. 
These observations in human patients suggest a detrimental effect of TREM2 haploinsufficiency 
on tau pathology. Surprisingly, in a tauopathy mouse model, complete loss of TREM2 function 
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had no effect on tau pathology, while protecting against brain atrophy22. These findings highlight 
the need to assess the effects of TREM2 haploinsufficiency in AD models.  
We investigated how TREM2 haploinsufficiency, a model relevant to AD cases carrying 
hemizygous risk variants, affects microglial function and tau pathology. Using in vivo two-photon 
microscopy to visualize microglial motility, we found that TREM2 haploinsufficiency resulted in 
an age-dependent impairment in microglial injury response without affecting baseline motility. 
Interestingly, complete loss of TREM2 resulted in a milder impairment in injury-induced motility 
compared to TREM2 haploinsufficiency. We then investigated the effects of TREM2 
haploinsufficiency and complete deficiency on tau pathology in mice expressing mutant human 
tau (P301S). Our findings demonstrated a robust increase in tau pathology in TREM2 
haploinsufficient mice, an effect that was not observed in TREM2 knockout mice. We further 
investigated how TREM2 haploinsufficiency and complete deficiency affect tau-mediated 
deficits.  
 
2.4 Results 
	
TREM2 Haploinsufficiency Causes an Age-Dependent Impairment in Microglia’s Injury 
Response 
Microglia carry out critical functions of surveying the brain and responding to injury23,24. 
To address the effect of TREM2 on microglial surveillance, we used in vivo two-photon imaging 
to examine microglial motility in 3–5-month-old TREM2+/+, TREM2+/– and TREM2-/- mice crossed 
to Cx3cr1GFP/+ mice, in which microglia express enhanced green fluorescent protein (eGFP) 
driven by the Cx3cr1 promoter25. Analysis of a 10-minute time-lapse recording of cortical 
microglia showed no differences in the baseline properties of microglia across the three 
genotypes, including average speed of process extension and retraction and total change in 
process length (Fig. 1 A–B). TREM2 also had no effect on microglial cell density or cell body 
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size at baseline (SI Appendix, Fig. S1 A–B). Moreover, in response to a laser-induced focal 
tissue injury, microglia from young TREM2+/+, TREM2+/– and TREM2-/- mice exhibited no 
difference in cell density (Fig. 1 C), cell body size (SI Appendix, Fig. S1C), or the density of 
microglial processes extending towards the injury site (Fig. 1 D-E, Movie S1).  
Given the established association of TREM2 with age-related diseases1-3,26, we next 
examined the effects of TREM2 on microglial motility in 9–14-month-old TREM2+/+, TREM2+/– 
and TREM2–/– mice. At baseline, the average speed and total change in process length did not 
differ across genotypes (Fig. 1 F–G). Microglial cell density or cell body size also remained 
similar (SI Appendix, Fig. S1 D-E). Strikingly, in response to focal tissue injury, microglia from 
older TREM2+/– mice demonstrated a significantly reduced response to injury compared to wild-
type microglia, as evidenced by fewer microglial processes extending towards the site of injury 
at any given time point (Fig. 1 I-J, Movie S2). TREM2–/– microglia showed a significant, yet 
milder attenuation in response size compared to TREM2+/– (Fig. 1 I-J, Movie S2). TREM2+/– 
microglia were the slowest to respond, extended the fewest processes towards the site of injury, 
and did not reach the injury site within 60 minutes (Fig. 1 I, Movie S2). TREM2-/- microglia, on 
the other hand, were able to reach the injury site within 60 minutes, similar to wild-type microglia 
(Fig. 1 I, Movie S2). The impairment in TREM2+/– and TREM2-/- microglia’s responses were not 
associated with differences in microglial density (Fig. 1 H) or activation state, as evidenced by 
the unaltered cell body size (SI Appendix, Fig. S1F). Moreover, there was no correlation 
between ablation size and response (SI Appendix, Fig. S1G), indicating that the reduced 
response sizes in TREM2-deficient microglia were not due to smaller injuries. Thus, surprisingly, 
TREM2 haploinsufficiency attenuates the in vivo microglial response to tissue injury in an age-
dependent manner and to a greater extent than complete TREM2 deficiency. 
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TREM2 Haploinsufficiency and Complete Deficiency Differentially Regulate the Microglial 
Transcriptome in the Presence and Absence of Tauopathy 
Next, to identify microglial pathways regulated by TREM2 in an unbiased fashion, we 
performed RNA sequencing (RNAseq) of adult microglia isolated using CD11b magnetic beads 
from young TREM2+/+, TREM2+/– and TREM2–/– mice. We confirmed the purity of our adult-
isolated microglia, as their transcriptome closely matched a previously published microglial 
transcriptome27 (Fig. 2 A). TREM2 haploinsufficiency and complete deficiency altered the 
microglial transcriptome in unique ways (Fig. 2 B). 107 transcripts were significantly different 
between TREM2+/– and TREM2–/– (Fig. 2 C). Ingenuity pathway analysis (IPATM) revealed 
cellular movement as the most significantly altered biological pathway in TREM2+/– microglia 
compared to TREM2-/- (Fig. 2 D), consistent with our in vivo imaging finding that TREM2+/– 
microglia exhibited greater impairment in their injury response than TREM2-/- (Fig. 1 J). 
Interestingly, these transcriptomic alterations in young TREM2+/– microglia preceded the 
impaired injury response seen in aged TREM2+/– microglia. In addition, multiple pathways 
pertaining to inflammation were significantly altered between TREM2+/– and TREM2–/– microglia, 
such as immune cell trafficking and inflammatory response (Fig. 2 D), suggesting differential 
regulation of inflammation in TREM2+/– versus TREM2-/- microglia.   
The rare R47H missense variant in TREM2 is associated with increased risk for 
tauopathies2,3,26,28 and hyperphosphorylation of tau in AD carriers19. We next investigated how 
TREM2 affects tau pathology and tau-associated deficits in the P301S tauopathy mouse model 
(Prnp-MAPT*P301S)29. The effects of TREM2 haploinsufficiency and complete loss of TREM2 
on tau-induced transcriptional changes were examined at 8-9 months of age (SI Appendix, Fig. 
S2A), when P301S mice exhibit significant tau inclusions, microgliosis, and neuronal loss29. 
Compared with P301S+ TREM2+/+ mice, there were 232 differentially expressed transcripts in 
P301S+ TREM2+/– mice (Fig. 3 A). These transcripts were significantly enriched for pathways 
pertaining to microglial development, such as TGFβ signaling4, and inflammation, such as IL2 
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STAT5 signaling and TNFα signaling via NF-κB (SI Appendix, Fig. S2B). To validate these 
pathways, we performed quantitative real-time PCR of pro- and anti-inflammatory markers. 
Consistent with tau-mediated inflammatory responses, expression of P301S human tau 
significantly increased levels of pro-inflammatory cytokines TNF-α, IL-1α, and IL-1β (SI 
Appendix, Fig. S3). Importantly, TREM2+/– resulted in significantly elevated levels of TNF-α and 
IL-1α compared to P301S+ TREM2+/+ mice, but had no effects on anti-inflammatory markers 
VEGF1, Cox2, or IL-34 (SI Appendix, Fig. S3). Differentially expressed genes in P301S+ 
TREM2-/-, on the other hand, were significantly enriched for genes related to metabolism, such 
as oxidative phosphorylation, glycolysis, and MTORC1 signaling (SI Appendix, Fig. S2C). Direct 
comparison of P301S+ TREM2+/– and P301S+ TREM2-/- revealed that of the 389 differentially 
expressed transcripts, there was a significant enrichment of complement-related genes and 
inflammatory response genes (Fig. 3 B).  
 
TREM2 Haploinsufficiency Exacerbates Tau Pathology in P301S Mice 
We then assessed how partial and complete loss of TREM2 affects tau aggregation. 
Immunohistochemistry with the AT8 antibody, which recognizes two phosphorylation sites on 
tau (pS202, pT205), revealed a significant increase in the AT8+ area in the cortex of P301S+ 
TREM2+/– mice compared to P301S+ TREM2+/+ and P301S+ TREM2-/- (Fig. 4 A-B) and a trend 
towards increased AT8 pathology in the hippocampus (Fig. 4 C-D). In contrast, there was no 
difference in AT8 load between P301S+ TREM2–/– and P301S+ TREM2+/+ mice in hippocampus 
and cortex (Fig. 4 A-D), consistent with a recent finding by Leyns et al 22. We also performed 
immunohistochemistry with the MC1 antibody, which detects a pathological conformation of tau 
30. Consistent with the differential effects induced by TREM2+/– and TREM2-/- on AT8 pathology, 
P301S+ TREM2+/– mice had significantly greater MC1+ area than P301S+ TREM2-/- in cortex 
(Fig. 4 E-F) and in hippocampus (Fig. 4 G-H). Similarly, the MC1+ area in the hippocampus of 
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P301S+ TREM2+/– mice, most notably in the mossy fibers, was significantly greater than in 
P301S+ TREM2+/+ mice (Fig. 4 G-H). A similar trend was observed in the cortex (Fig. 4 E-F). In 
sharp contrast, the MC1+ area trended towards a decrease in P301S+ TREM2-/- mice compared 
to P301S+ TREM2+/+ mice (Fig. 4 F and H). Thus, TREM2 haploinsufficiency, but not complete 
loss of TREM2, enhances tau pathology. 
 
Differential Effects of Partial and Complete TREM2 Deficiency on Atrophy and 
Microgliosis in P301S Mice 
Next, we investigated how TREM2 haploinsufficiency and complete deficiency affect tau-
induced neurodegeneration. At 8-9 months of age, there were similar levels of hippocampal 
neuronal loss in P301S mice regardless of TREM2 genotype (SI Appendix, Fig. S4A-B) and tau-
induced atrophy could not yet be detected in cortex (SI Appendix, Fig. S4C). However, complete 
TREM2 deficiency resulted in a protection against hippocampal atrophy, as evidenced by the 
smaller lateral ventricle area (Fig. 5 A-B), and a trend towards increased hippocampal area (Fig. 
5 C). This result is in agreement with a previous report that showed that complete TREM2 
deficiency protected against brain atrophy in P301S mice 22. Compared to P301S+ TREM2+/+, 
TREM2 haploinsufficiency did not significantly affect atrophy at 8-9 months (Fig. 5 A-C) or at 10-
11 months of age (Fig. 5 D-E). However, compared to wild-type mice, P301S+ TREM2+/–, but 
not P301S+ TREM2+/+ mice exhibited significantly more severe atrophy (Fig. 5 D-E). 
We next evaluated how TREM2 levels affect tau-induced microgliosis, a canonical 
hallmark of AD pathology recapitulated in P301S mice 29. Analysis of Iba1 immunoreactivity in 
the hippocampus revealed an expected significant increase in microglial number induced by 
P301S tau (Fig. 6 A-B). Interestingly, compared to P301S+ TREM2+/+, complete TREM2 
deficiency, but not haploinsuffciency, resulted in a trend towards reduced microglial density, 
(Fig. 6 A-B). Moreover, the number of microglia positively correlated with MC1+ area (Fig. 6 C), 
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supporting the idea that elevated tau pathology is associated with inflammatory responses in 
microglia.  
To further characterize how TREM2 levels affect tau-mediated microglial activation, we 
performed morphological analyses using 3D renderings of confocal images (Fig. 6 D). 
Compared to TREM2+/+, TREM2 haploinsufficiency in P301S mice induced significantly 
shortened processes (Fig. 6 E) and fewer branches (Fig. 6 F), indicating strong tau-mediated 
microglial activation. In contrast, complete loss of TREM2 in P301S mice resulted in a failure to 
induce morphological changes associated with microglial activation; microglia from P301S+ 
TREM2–/– mice exhibited similar process length and arborization as non-activated microglia from 
wild-type (TREM+/+) mice (Fig. 6 D-F).  
 
2.5 Discussion 
	
Our study highlights multiple findings in which TREM2 haploinsufficiency resulted in 
stronger or different phenotypes than complete TREM2 deficiency. TREM2 haploinsufficiency 
led to a greater age-dependent impairment in microglia’s response to injury compared to 
complete TREM2 deficiency. Moreover, TREM2 haploinsufficiency exacerbated tau pathology, 
atrophy and inflammation. On the contrary, complete loss of TREM2 protected against atrophy 
and reduced microgliosis. Interestingly, complete loss of TREM2 was also associated with 
trends towards reduced MC1+ pathology. These results highlight multiple TREM2 phenotypes 
that are gene-dose independent. Since hemizygous TREM2 variants are associated with 
elevated risk for AD, TREM2 haploinsufficiency may be a more relevant model to study how 
TREM2 contributes to AD pathogenesis. Indeed, complete loss of TREM2 in humans results in 
Nasu-Hakola disease31, which could be driven by mechanisms that are distinct from those of 
AD.  
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  As the resident immune cells in the brain, microglia need to respond robustly to injury, 
especially in neurodegenerative brains that have increased neuronal death and accumulation of 
abnormal protein aggregates. Using in vivo imaging, we showed that TREM2 haploinsufficiency 
impairs microglia’s injury-induced response in an age-dependent manner and to a greater 
degree than complete loss of TREM2 (Fig. 1 J, Movie S2). It is interesting that this result is 
present in aged, but not young mice. This finding mirrors the role of TREM2 in the development 
of late-onset AD. Notably, there was no impairment in baseline motility (Fig. 1 F-G), suggesting 
that TREM2 modulates microglial pathways specifically related to injury response. This injury-
specific modulation of motility may contribute to TREM2’s implication in neurodegeneration, 
where neuronal injury is abundant. This type of differential modulation of baseline and injury-
induced motility has been observed previously in the microglia field. For example, the purinergic 
receptor P2RY12 was found to slow down microglia’s response to ATP/ADP released during 
injury without affecting baseline motility32.  
Aged TREM2 haploinsufficient microglia were significantly slower to respond to injury 
and extended fewer processes towards the site of injury throughout the 60-minute imaging 
session (Movie S2). Interestingly, TREM2 deficient microglia showed an intermediate phenotype 
between TREM2 haploinsufficient and wild-type microglia. On average, they extended more 
processes towards the site of injury than TREM2 haploinsufficient microglia, and they were able 
to reach the site of injury within 60 minutes (Movie S2). This gene-dose independent 
phenomenon may be driven by compensatory mechanisms in microglia completely lacking 
TREM2 from development, while TREM2 haploinsufficiency could elicit different types of 
compensatory changes via modulation of TREM2 expression from the existing allele. Our 
RNAseq analyses of TREM2+/– and TREM2-/- microglia revealed a significant difference in the 
cellular movement pathway induced by TREM2 deficiency (Fig 2. D), consistent with a previous 
study that looked at TREM2+/+ and TREM2-/- microglia33. Interestingly, the transcriptional 
changes in TREM2 haploinsufficient microglia occurred prior to the development of the impaired 
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injury response. These observations are consistent with a two-hit hypothesis: young TREM2 
haploinsufficient microglia can maintain normal function, but those challenged by age or 
pathological conditions, such as tauopathy, are unable to do so.  
Remarkably, TREM2 haploinsufficiency exacerbated tau pathology, whereas complete 
TREM2 deficiency did not (Fig. 4), yet another phenotype that was not gene-dose dependent. 
Of note, patients with the R47H TREM2 variant have increased tau pathology13, similar to 
TREM2 haploinsufficient tauopathy mice. One likely explanation for the lack of effect of 
complete TREM2 deficiency on multiple phenotypes is that complete loss of TREM2 may result 
in compensatory changes. Indeed, a previous study showed that in the absence of TREM2, 
expression of homeostatic microglial genes was not suppressed, but rather fully preserved and 
even slightly increased, supporting the possibility of compensation 33. Moreover, we observed 
transcriptional changes between TREM2+/– and TREM2-/- microglia that may underlie gene-dose 
independent phenotypes. Inflammatory pathways were altered at the transcriptional level 
between TREM2+/– and TREM2-/- microglia from young mice (Fig. 2 D), highlighting early-onset, 
inherent TREM2-dependent changes in microglial activation that persisted in older, disease 
states (Fig S3, Fig. 6).  
The P301S mouse model begins to show neuronal loss at 9-10 months of age29. Neither 
TREM2 haploinsufficiency nor complete deficiency exacerbated neuronal loss at 8-9 months of 
age. However, complete loss of TREM2 protected against tau-induced atrophy (Fig. 5 A-C). Our 
results suggest that the increase in cortical volume seen by Leyns et al22 may not be due to a 
protection against neuronal loss, per se, as P301S+ TREM2-/- mice had a similar number of 
neurons as P301S+ TREM2+/+ mice (Fig. S4C). Instead, complete loss of TREM2 may increase 
cortical volume through other mechanisms, such as protection against loss of neuronal 
processes or, given TREM2’s implication in lipid sensing10, through an increase in the brain’s 
lipid content. In contrast to the neuroprotective effect of complete loss of TREM2, partial loss of 
TREM2 appears to be detrimental, highlighted by the significant increase in lateral ventricle area 
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at 10-11 months of age compared to wild-type mice (Fig. 5 E). It is interesting to note that 
complete loss of TREM2 resulted in a trend towards reduced late-stage tau pathology and 
reduced atrophy, while TREM2 haploinsufficiency exacerbated tau pathology and exacerbated 
atrophy. It remains to be determined whether tau pathology and microglial activation work 
together or independently to cause brain atrophy.  
We also detected increased expression of pro-inflammatory cytokines in P301S+ 
TREM2+/– mice (Fig. S3), a finding consistent with the cytokine profiles in R47H carriers with 
AD20. However, it is unclear whether the increased inflammatory state is a cause or 
consequence of the increased tau pathology present in both TREM2+/– mice and patients with 
the R47H variant19. Interestingly, in amyloid mouse models, TREM2 haploinsufficiency did not 
affect the expression of pro- or anti-inflammatory markers at early or later stages of amyloid 
pathology8, but reduced microglia number10. These studies, in conjunction with our data, 
suggest that TREM2 haploinsufficiency differentially modulates inflammation in the contexts of 
amyloid and tau pathology. On the other hand, P301S+ mice completely lacking TREM2 have 
been shown to have lower levels of pro-inflammatory markers22, as well as reduced microglial 
density and a resting state morphology. Together, these results, along with our RNAseq data 
(Fig. 2 D, Fig. 3 B, Fig. S2B), suggest inflammation as a possible mechanism by which TREM2 
haploinsufficiency versus complete deficiency result in apparent opposing phenotypes, such as 
their effects on tau pathology. Microglia have been implicated in the spread of tau pathology34 
and their activation state could contribute to how they respond in the context of tauopathy. 
Indeed, we found a significant positive correlation between microglial density and tau pathology 
(Fig. 6 C). 
Our surprising discovery that TREM2 haploinsufficiency exerts a more robust impairment 
in microglial function and exacerbation of tau pathology compared to complete loss of TREM2 
highlights the plasticity of microglia in response to TREM2 deficiency. The potential detrimental 
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effects of TREM2 haploinsufficiency can provide insight into how TREM2 contributes to AD 
pathogenesis, and inform potential TREM2-targeted therapeutic strategies. 
	
2.6 Methods 
	
Detailed procedures for all methods below are described in the SI Appendix. 
Mice. All animal procedures were carried out under protocols approved by the University of 
California, San Francisco, Institutional Animal Care and Use Committee.  
In vivo imaging. Intravital imaging using two-photon microscopy was performed with thinned-
skull windows as previously described24.  
Antibodies, immunohistochemistry and image analysis. Immunohistochemistry and image 
analysis were performed by experimenters blinded to the genotypes. The code was not broken 
until all analyses were completed.  
Adult microglia isolation and quantitative reverse-transcription PCR. Adult microglia were 
isolated from TREM2+/+, TREM2+/– and TREM2-/- mice as described previously35.  
RNA-sequencing and analysis. RNAseq libraries were prepared with either Ovation RNAseq 
system v2 kit (NuGEN) or Lexogen’s QuantSeq 3’ mRNA-Seq Library Prep Kit. All RNAseq data 
has been deposited within the Gene Expression Omnibus (GEO) repository 
(www.ncbi.nlm.nih.gov/geo), accession number GSE118630.  
Statistical analysis. Data were analyzed with Graphpad Prism v.7 (GraphPad), STATA12 
(StataCorp LP), or R (R Foundation for Statistical Computing). Multilevel mixed-effects linear 
regression model fit using STATA12 was used to compare curves for young and aged mice in 
response to injury. For cluster analyses of multiple measurements from individual mice, we used 
the R package lmer. Outliers were removed based on Graphpad’s outlier analysis algorithm. All 
animals were included for statistical analyses unless otherwise noted.  
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2.9 Supplementary Text 
	
Mice. Cx3cr1GFP/GFP (https://www.jax.org/strain/005582) were crossed with TREM2+/-1 to obtain 
Cx3cr1GFP/+ TREM2+/+, Cx3cr1GFP/+ TREM2+/-, and Cx3cr1GFP/+ TREM2-/- mice. P301S transgenic 
mice (https://www.jax.org/strain/008169) were crossed with TREM2+/- to generate P301S+ 
TREM2+/+, P301S+ TREM2+/-, P301S+ TREM2-/- and TREM2+/+ mice. Mice of both genders 
were used. All animal procedures were carried out under protocols approved by the University 
of California, San Francisco, Institutional Animal Care and Use Committee.   
 
Primary antibodies. Monoclonal antibodies were as follows: MC1 (a kind gift from P. Davies, 
1:500) and AT8 (MN1020, Thermo Scientific, 1:500). Polyclonal antibodies were as follows: anti-
Iba1 (019-19741, Wako, 1:500) and anti-NeuN (MAB377, Millipore, 1:500). Immunoreactivity 
was detected using Alexa Fluor goat anti-mouse or rabbit secondary antibodies in the 488- or 
555-nm range (Jackson ImmunoResearch, 1:500).  
 
In vivo imaging. For intravital imaging using two-photon microscopy, thinned-skull windows 
were made in Cx3cr1GFP/+ TREM2+/+, Cx3cr1GFP/+ TREM2+/-, and Cx3cr1GFP/+ TREM2-/- as 
previously described 2. Briefly, mice were anesthetized using ketamine-xylazine, the skull was 
exposed, and a small area over somatosensory cortex was thinned manually and with a high-
speed drill (K.1070 High Speed Rotary Micromotor drill; Foredom). Mice were fixed onto a 
custom-made head plate and imaged with an Ultima IV multiphoton microscope (Bruker) 
equipped with MaiTai DeepSee-eHP lasers (Spectra Physics) tuned to 915 nm. Z-stacks of 
images spanning 50-70µm from the pial surface were obtained with a Nikon 40x 0.8 N.A. water-
immersion lens. Z-stacks of images were acquired every 30 seconds (for baseline motility 
recordings) or every 3 minutes (for laser-induced injury recordings). Time-lapse movies were 
generated by projecting images of each time point along the z-axis and aligning them over time 
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with the StackReg plug-in in ImageJ software (NIH). Extensions and retractions of processes 
during baseline recordings were manually traced using the mTrackJ plugin. The movement of 
microglial processes toward a laser ablation was analyzed as described previously 2,3, by 
normalizing the number of processes near the site of injury at each time point to the overall 
microglial density at that time point.  
 
Immunohistochemistry and image analysis. Mice were transcardially perfused with PBS. 
Hemibrains were flash frozen at -80°C for biochemical analyses; the other half was placed in 
4% paraformaldehyde for 48 h, followed by 30% sucrose for 48 h at 4°C.  A freezing microtome 
(Leica) was used to make 30µm-thick brain sections. 6-8 free-floating sections per mouse were 
washed in PBS, permeabilized with PBS containing 0.5% Triton X-100 for 10 min then blocked 
in PBS containing 10% normal goat serum (NGS) for 1 hour. Sections were then placed in PBS 
with 5% normal goat serum and primary antibodies overnight at 4°C. The following day, sections 
were washed in PBS containing 0.1% Triton X-100, incubated with Alexa-conjugated secondary 
antibodies in PBS with 5% normal goat serum and washed in PBS containing 0.1% Triton X-
100. Images were acquired on a Keyence BZ-X700 microscope using a 10x objective. 
Quantification was performed using ImageJ software (NIH). For quantification of NeuN staining, 
images were analyzed with Keyence BZ Analyzer software for deconvoluted fluorescence 
quantification. Experimenters quantifying immunoreactivity were blinded. For 3D reconstruction 
of microglia, 40x line-scanning confocal images were taken of the CA3 hippocampal region, 1 
field of view per mouse. 3D reconstruction was done using Imaris software.  
 
RNA isolation and quantitative reverse-transcription PCR. Cortices that had been flash 
frozen were dissected and homogenized with a 21G needle in RLT buffer with 1% β-
mercaptoethanol. RNA was isolated with the RNeasy Mini-Kit (Qiagen), and the remaining DNA 
was removed by incubation with RNase-free DNase (Qiagen). Purified mRNA was then 
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converted to cDNA using the iScript Reverse Transcription Supermix (BioRad). Quantitative RT-
PCR was performed on the ABI 7900 HT sequence detector (Applied Biosystems) with SYBR 
Green PCR master mix (Applied Biosystems). The average value of three replicates for each 
sample was expressed as a threshold cycle (Ct), at which the fluorescence signal starts to 
increase rapidly. Then, the difference (ΔCt) between Ct values for the transcript of interest and 
for mouse GAPDH was calculated for each sample. The relative gene expression for each 
sample was determined by 2-ΔCt and expressed as fold change compared to TREM2+/+. The 
following primers were used for quantitative RT-PCR: TNFα (forward:  
CATCAGTTCTATGGCCCAGA; reverse: TGCTCCTCCACTTGGTGGTT); IL-1α (forward: 
CACCTTACACCTACCAGAGTGATTTG; reverse: TGTTGCAGGTCATTTAACCAAGTG); IL-1β 
(forward: TGCCACCTTTTGACAGTGATG; reverse: TGATGTGCTGCTGCGAGATT); TGFβ 
(forward: AACCCCCATTGCTGTCCCGTG; reverse: GCGCTGAATCGAAAGCCCTGT); VEGF1 
(forward: GCTGCACCCACGACAGAAGGA; reverse: TCGTTACAGCAGCCTGCACAGC); Cox2 
(forward: GTACCGCAAACGCTTCTCCCTG; reverse: CCTCCAAAGGTGCTCGGCTTCCA); IL-
34 (forward: CTTTGGGAAACGAGAATTTGGAGA; reverse: 
GCAATCCTGTAGTTGATGGGGAAG); GAPDH (forward: TGGCCTTCCGTGTTCCTAC;  
reverse: GAGTTGCTGTTGAAGTCGCA) 
 
Adult microglia isolation. Adult microglia were isolated from TREM2+/+, TREM2+/- and TREM2-
/- as described previously4. Briefly, brains were perfused with ice-cold PBS and minced with a 
razor blade in RPMI 1640 containing 2 mM l-glutamine (Mediatech), 40 U/mL dispase, and 6% 
collagenase type 3 (Worthington Biochemicals). After incubation for 15 min with DNase I (10 U; 
Roche Applied Science) at 37 °C, enzymes were inactivated with an equal volume of PBS 
containing 2 mM EDTA and 2% FBS. Brains were triturated thoroughly, passed through a 70-
µm filter, centrifuged at 300 × g for 5 min at 18 °C, and resuspended in fluorescence-activated 
cell sorting (FACS) buffer (500 mM EDTA, 0.5% BSA, 0.09% sodium azide in PBS). Myelin-
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removal beads (Miltenyi Biotec) were added for 15 min at 4 °C, and the cells were centrifuged at 
300 × g and resuspended in FACS buffer. Cells were magnetically separated and selected for 
CD11b as described above. CD11b+ cells were centrifuged, and RNA was extracted (Qiagen 
RNeasy Kit) for RNA-sequencing. 
 
RNA-sequencing and analysis. RNA-seq libraries were prepared with Ovation RNA-seq 
system v2 kit (NuGEN) from 4 replicates per genotype (total: 12 samples). Briefly, total RNA is 
reverse-transcribed to synthesize the first-strand cDNA using a combination of random 
hexamers and a poly-T chimeric primer. The RNA template is then partially degraded by heating 
and the second strand cDNA is synthesized using DNA polymerase. The double-stranded DNA 
is then amplified using single primer isothermal amplification (SPIA). SPIA is a linear cDNA 
amplification process in which RNase H degrades RNA in DNA/RNA heteroduplex at the 5′-end 
of the double-stranded DNA, after which the SPIA primer binds to the cDNA and the polymerase 
starts replication at the 3′-end of the primer by displacement of the existing forward strand. 
Random hexamers are then used to amplify the second-strand cDNA linearly. Finally, libraries 
from the SPIA amplified cDNA were made using the Ultralow DR library kit (NuGEN). After 
quality control analysis with a Bioanalyzer, the libraries were sequenced using a HiSeq 4000 
instrument (Illumina), generating between 58 and 141 (average: 91) million reads/sample. 
Quality control was performed on base qualities and nucleotide composition of sequences. 
Alignment to the M. musculus (mm10) refSeq (refFlat) reference gene annotation was 
performed using the STAR spliced read aligner5 with default parameters. Additional quality 
control was performed after the alignment to examine: the level of mismatch rate, mapping rate 
to the whole genome, repeats, chromosomes, key transcriptomic regions (exons, introns, UTRs, 
genes), insert sizes, AT/GC dropout, transcript coverage and GC bias. Between 87 and 90% 
(average: 89.3%) of the reads mapped uniquely to the mouse genome. Total counts of read-
fragments aligned to candidate gene regions were derived using the HTSeq program 
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(www.huber.embl.de/users/anders/HTSeq/doc/overview.html) with mouse mm10 (Dec. 2011) 
refSeq (refFlat table) as a reference and used as a basis for the quantification of gene 
expression. Only uniquely mapped reads were used for subsequent analyses. Two samples 
(one TREM2+/- and one TREM2-/-) with the lowest alignment rates and that clustered away from 
the remaining samples were excluded from subsequent analyses. After regressing by sex, 
Bioconductor packages edgeR6 and limma-voom7 were used for differential expression analysis, 
which included four TREM2+/+, three TREM2+/-, and three TREM2-/- replicates. The trimmed 
mean normalization (TMM) method was used to normalize the counts after excluding genes with 
0 count across all samples/libraries. Statistical significance of the differential expression was 
determined at a p-value < 0.005.  For figure 3, libraries were prepared using Lexogen’s 
QuantSeq 3’ mRNA-Seq Library Prep Kit, 4 replicates per genotype (total: 16 samples). 
Sequencing and analysis was performed in a similar manner as detailed above. RNAseq data 
has been deposited within the Gene Expression Omnibus (GEO) repository 
(www.ncbi.nlm.nih.gov/geo), accession number GSE107293.   
 
Statistical analysis. 
Data were analyzed with Graphpad Prism v.7 (GraphPad), STATA12 (StataCorp LP), or R (R 
Foundation for Statistical Computing). Multilevel mixed-effects linear regression model fit using 
STATA12 was used to compare curves for young and aged mice in response to injury. For 
cluster analyses of multiple measurements from individual mice, we used the R package lmer. 
Outliers were removed based on Graphpad’s outlier analysis algorithm. All animals were 
included for statistical analyses unless otherwise noted. 
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2.11 Legends for Supplementary Movies 
	
Movie S1 Video file showing microglial responses to a localized laser-induced injury in vivo in 
young TREM2+/+, TREM2+/- and TREM2-/- mice over a 60-minute time period. 
 
Movie S2 Video file showing microglial responses to a localized laser-induced injury in vivo in 
aged TREM2+/+, TREM2+/- and TREM2-/- mice over a 60-minute time period. 
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2.12 Main Figures 
	
Figure 2.1 TREM2 haploinsufficiency causes an age-dependent impairment of 
microglia’s injury response in vivo. (A–E) Quantification of microglial motility in 3-5-month 
old mice. Quantification of the average speed per microglial process (A) and total change in 
length of microglial processes (B) during 10-minute baseline recordings from 3- to 5-month-
old mice. TREM2+/+, n=7 recordings from 7 mice; TREM2+/–, n=9 recordings from 9 mice; 
TREM2–/–, n=10 recordings from 10 mice. (C) Microglial density for young mice from laser-
induced tissue injury videos. TREM2+/+, n=10 recordings from 9 mice; TREM2+/–, n=11 
recordings from 10 mice; TREM2–/–, n=12 recordings from 10 mice. (D) Representative still 
images at 3 min, 21 min, 39 min and 57 min from the microglial responses to injury in young 
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mice. Laser ablations are outlined with smaller white circles. The response was normalized to 
microglial density at each time point, denoted by larger white circles. Scale bar: 20µm. (E) 
Quantification of normalized microglial responses from young mice towards focal laser-
induced tissue injury over a period of 60 minutes from time of injury. TREM2+/+, n=7 injuries 
from 7 mice; TREM2+/–, n=11 injuries from 10 mice; TREM2–/–, n =12 injuries from 10 mice. 
(F–K) Quantification of microglial motility in 9- to 14-month old mice. (F) Quantification of the 
average speed per microglial process and (G) total change in length of processes during 10-
minute baseline recordings from 9-14-month old mice. TREM2+/+, n=10 recordings from 7 
mice; TREM2+/–, n=10 recordings from 9 mice; TREM2–/–, n=10 recordings from 9 mice. (H) 
Microglial density for aged mice during laser-induced tissue injury experiments. TREM2+/+, 
n=7 recordings from 6 mice; TREM2+/–, n=13 recordings from 10 mice; TREM2–/–, n=12 
recordings from 9 mice. (I) Representative still images at 3 min, 21 min, 39 min and 57 min 
from the microglial responses to injury in aged mice. Laser ablations are outlined with smaller 
white circles.  Response size was normalized to microglial density at each time point, denoted 
by larger white circles. Scale bar: 20µm. (J) Quantification of normalized microglial responses 
from aged mice towards focal laser-induced tissue injury was measured over a period of 60 
minutes from time of injury. TREM2+/+, n=6 injuries from 5 mice; TREM2+/–, n =13 injuries from 
10 mice; TREM2-/-, n =12 injuries from 9 mice. (****p<0.0001, STATA mixed-effects 
modeling). Values are expressed as mean ± SEM. Data were analyzed using one-way 
ANOVA with Bonferroni post-hoc analyses for all panels except for (E) and (J), which were 
analyzed using STATA mixed-effects modeling. 
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Figure 2.2 Differential effects of partial and complete loss of TREM2 on the microglial 
transcriptome. (A) RNA sequencing of microglia isolated from the forebrain of 3- to 4-month 
old mice (TREM2+/+, n= 4 samples from 8 mice; TREM2+/–, n= 3 samples from 6 mice; TREM2-/-, 
n=3 samples from 6 mice).  Expression levels of the top 100 most enriched transcripts in 
astrocytes (AS), endothelial cells (EN), microglia (MG), neurons (NE) and oligodendrocytes 
(OG), as identified by Zhang et al. (27). Columns 1-5: data from Zhang et al. Columns 6-15: 
expression data in microglia from TREM2+/+, TREM2+/– and TREM2-/- mice. Shades of red 
correspond to increased levels compared to average gene expression and shades of blue 
correspond to decreased levels. (B) Heat map representing significantly altered transcripts 
(p<0.005) across all genotypes. Samples are in columns and genes are in rows. Shades of red 
represent upreglation, while shades of green represent downregulation. (C) Venn diagram 
illustrating the number and overlap of transcripts that were significantly altered between the two 
indicated genotypes (p<0.005). (D) Ingenuity pathway analysis (IPATM) of top six enriched 
disease and biological function pathways from 107 transcripts that were significantly altered in 
TREM2-/- microglia compared to TREM2+/– microglia (p<0.005). Bars indicate –log (p-value) of 
enrichment. Red dotted line corresponds to p=0.05. 
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Figure 2.3 Differential effects of partial and complete loss of TREM2 on P301S-induced 
transcriptional changes.  (A) Venn diagram illustrating the number and overlap of transcripts 
that were significantly altered between the two indicated P301S+ genotypes from 8- to 9-month-
old mice (p<0.005, 4 mice/genotype, 1 mouse/sample). (B) GSEA analysis using the hallmark 
database on significant differentially expressed transcripts between partial versus complete loss 
of TREM2 in P301S mice. The top 10 most enriched pathways are shown. The fraction on the 
bar graph indicates the total number of genes curated in the database for the specified term 
(denominator) and the number of overlapping genes in the inputted RNAseq dataset 
(numerator).  
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Figure 2.4 TREM2 haploinsufficiency exacerbates tau pathology in P301S+ mice. (A) 
Representative images of AT8 immunostaining in the cortex of 8- to 9-month-old mice. Scale 
bar: 100µm. (B) Quantification of the percentage of AT8+ area in the cortex of P301S+ 
TREM2+/+, n=9 mice; P301S+ TREM2+/–, n=25 mice; P301S+ TREM2-/-, n=9 mice; 6-8 
sections/mouse (*p<0.05, STATA mixed-effects modeling). (C) Representative images of AT8 
immunostaining in the hippocampus of 8- to 9-month-old mice. Scale bar: 300µm. (D) 
Quantification of the percentage of AT8+ area in the hippocampus of P301S+ TREM2+/+, n=9 
mice; P301S+ TREM2+/–, n=25 mice; P301S+ TREM2-/-, n=10 mice; 6-8 sections/mouse. (E) 
Representative images of MC1 immunostaining in the cortex of 8- to 9-month-old mice. Scale 
bar: 300µm. (F) Quantification of the percentage of MC1+ area in the cortex of P301S+ 
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TREM2+/+, n=9 mice; P301S+ TREM2+/–, n=25 mice; P301S+ TREM2-/-, n=9 mice; 7-16 
sections/mouse (**p<0.01, R mixed-effects modeling). (G) Representative images of MC1 
immunostaining in the hippocampus of 8- to 9-month-old mice. Scale bar: 100µm. (H) 
Quantification of the percentage of MC1+ area in the hippocampus of P301S+ TREM2+/+, n=9 
mice; P301S+ TREM2+/–, n=25 mice; P301S+ TREM2–/–, n=10 mice; 7-16 sections/mouse 
(**p<0.01, ***p<0.001, R mixed-effects modeling). Values are expressed as mean ± SEM. 
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Figure 2.5 Differential effects of partial and complete loss of TREM2 on atrophy in 
P301S+ mice. (A) Representative images of NeuN immunostaining from 8- to 9-month-old 
mice. Lateral ventricle outlined with a white dashed line. (B) Quantification of the lateral ventricle 
area of TREM2+/+, n=6 mice; P301S+ TREM2+/+, n=9 mice; P301S+ TREM2+/–, n=25 mice; 
P301S+ TREM2-/-, n=10 mice, 6-17 sections/mouse (*p<0.05, one-way ANOVA with Bonferroni 
post-hoc analysis). (C) Quantification of the hippocampal area in 8- to 9-month-old TREM2+/+, 
n=6; P301S+ TREM2+/+, n=9; P301S+ TREM2+/–, n=25; and P301S+ TREM2-/-, n=10 mice, 6-17 
sections/mouse. (D) Representative images of NeuN immunostaining from 10- to 11-month-old 
mice. Lateral ventricle outlined with a white dashed line. (E) Quantification of the lateral ventricle 
area of TREM2+/+, n=12 mice; P301S+ TREM2+/+, n=12 mice; P301S+ TREM2+/–, n=11 mice; 6-
8 sections/mouse (***p<0.001, one-way ANOVA with Bonferroni post-hoc analysis). Values are 
expressed as mean ± SEM. 
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Figure 2.6 Differential regulation of inflammation by partial and complete loss of TREM2 
in P301S+ mice. (A) Representative images of Iba1 immunostaining of microglia in the 
hippocampus of 8- to 9-month-old mice. Scale bar: 300µm. (B) Quantification of the number of 
microglia per millimeter squared in the hippocampus of TREM2+/+, n=5 mice; P301S+ TREM2+/+, 
n=9 mice; P301S+ TREM2+/–, n=25 mice; P301S+ TREM2-/-, n=10 mice; 6-17 sections/mouse 
(*p<0.05, R mixed-effects modeling). (C) Significant positive correlation between hippocampal 
percent MC1+ area and number of Iba1+ cells per mm2 (***p<0.001, linear regression). Each 
dot represents one animal. Graph depicts mean and 95% confidence intervals. Genotypes are 
color-coded according to key. (D) Representative images of hippocampal Iba1 immunostaining 
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and the corresponding 3D reconstructions using Imaris. Scale bar for 1st column with full view 
images: 40µm. Scale bar for 2nd and 3rd columns with zoomed-in images: 20µm. (E) 
Quantification of the length sum of microglial processes and (F) number of microglial branches 
in TREM2+/+, n=4 mice (35 cells); P301S+ TREM2+/+, n=7 mice (123 cells); P301S+ TREM2+/–, 
n=9 mice (169 cells); P301S+ TREM2-/-, n=5 mice (64 cells) (*p<0.05, ***p<0.001, one-way 
ANOVA with Bonferroni post-hoc analysis). Values are expressed as mean ± SEM.  
 
	  
	 51	
 
2.13 Supplementary Figures 
 
Figure S2.1 No difference in microglial cell density or cell body size across genotypes in 
vivo. (A) Microglial cell body size and (B) microglial cell density at baseline in young mice. 
TREM2+/+, n=11 recordings from 10 mice; TREM2+/-, n=12 recordings from 12 mice; TREM2-/-, 
n=12 recordings from 11 mice. (C) Microglial cell body size during laser-induced injury in young 
mice. TREM2+/+, n=10 recordings from 9 mice; TREM2+/-, n=11 recordings from 10 mice; 
TREM2-/-, n=12 recordings from 10 mice. (D) Microglial cell body size and (E) microglial cell 
density at baseline in aged mice. TREM2+/+, n=8 recordings from 6 mice; TREM2+/-, n=10 
recordings from 9 mice; TREM2-/-, n=14 recordings from 9 mice. (F) Microglial cell body size 
during ablation in aged mice. TREM2+/+, n=7 recordings from 6 mice; TREM2+/-, n=13 recordings 
from 10 mice; TREM2-/-, n=12 recordings from 9 mice. Data were analyzed using one-way 
ANOVA with Bonferroni post-hoc analyses. (G) Lack of correlation between ablation size and 
response in aged mice, R2=0.012. Values are expressed as mean ± SEM. 
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Figure S2.2 Differential effects of partial and complete loss of TREM2 on P301S-induced 
transcriptional changes. (A) RNA sequencing of brain tissue isolated from 8- to 9-month-old 
mice (4 mice/genotype, 1 mouse/sample). Heat map representing significantly altered 
transcripts (p<0.005) across all genotypes. Samples are in columns and genes are in rows. 
Shades of red represent upregulation, while shades of green represent downregulation. First 
three columns are all relative to TREM2+/+. Next two columns are relative to P301S+ TREM2+/+. 
Last column is a direct comparison between P301S+ TREM2+/- and P301S+ TREM2-/- (B–C) 
GSEA analyses using the hallmark database on significant differentially expressed genes 
between the indicated genotypes. The top 10 most enriched pathways are shown. The fraction 
on the bar graph indicates the total number of genes curated in the database for the specified 
term (denominator) and the number of overlapping genes in the inputted RNAseq dataset 
(numerator).  
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Figure S2.3 TREM2 haploinsufficiency increases levels of pro-inflammatory transcripts in 
P301S+ mice. Quantitative real-time PCR of pro- and anti-inflammatory markers in the cortex of 
8- to 9-month-old TREM2+/+, n=5 mice; TREM2+/-, n=4 mice; P301S+ TREM2+/+, n=7 mice; 
P301S+ TREM2+/-, n=6 mice. Samples were run in triplicates and averages of the three wells 
were used for quantification, normalized to GAPDH (*p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001, two-way ANOVA with Bonferroni post-hoc analyses). Values are expressed as 
mean ± SEM. 
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Figure S2.4 TREM2 deficiency does not affect the loss of NeuN-positive neurons in 
P301S+ mice.   (A) Representative images of NeuN+ neuronal density in the hippocampus of 8- 
to 9-month-old mice. Scale bar: 300µm. (B) Quantification of the number of NeuN+ puncta in the 
hippocampus and (C) cortex in TREM2+/+, n=6 mice; P301S+ TREM2+/+, n=9 mice; P301S+ 
TREM2+/-, n=25 mice; P301S+ TREM2-/–, n=10 mice; 6-17 sections/mouse (*p<0.05, R mixed-
effects modeling). Values are expressed as mean ± SEM. 
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Chapter 3: AD-linked TREM2 Mutation Induces Metabolic Changes in 
Neurons and Oligodendrocytes Associated with Toxicity  
	
 
3.1 Abstract 
The hemizygous R47H variant of TREM2, a microglia-specific gene in the brain, 
increases risk for late-onset Alzheimer’s disease (AD). To understand its pathogenicity, we 
generated knock-in mice in which mouse Trem2 was replaced with wild-type or R47H human 
TREM2. One allele of R47H-hTREM2 was sufficient to induce cognitive deficits and alter 
synaptic transmission. In knock-in mice with tau inclusions, R47H-hTREM2 exacerbated spatial 
learning and memory deficits only in female mice. Bulk, single-cell, and single-nuclei RNA-
sequencing of hippocampal tissue from female mice revealed R47H-induced global non-cell 
autonomous effects. Single-nuclei RNA-sequencing of cortex from AD patients with and without 
R47H-TREM2 established transcriptomic changes in oligodendrocytes that correlated 
significantly with those observed in the R47H tauopathy mouse model. By unraveling disease-
enhancing properties of the R47H mutation, our findings provide new directions for developing 
microglia-targeted AD therapies. 
 
3.2 Introduction 
Alzheimer’s disease (AD) is the most common form of late-onset dementia. In addition to 
the pathological hallmarks of amyloid plaques and neurofibrillary tangles composed of 
hyperphosphorylated tau, AD is also characterized by increased microglial activation and an 
upregulation of cytokines in the brain. These aberrant microglial phenotypes in AD have been 
largely considered responses to the toxic buildup of plaques and tangles. However, genome-
wide association studies have identified many risk alleles for late-onset sporadic AD that are 
highly expressed in microglia1-4, suggesting that microglial dysfunction can contribute to AD 
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pathogenesis. Among these risk alleles is TREM2, the strongest immune-gene risk factor 
identified to date. A heterozygous point mutation in TREM2, the R47H variant, significantly 
increases risk for late-onset AD1,2. 
TREM2 is a single transmembrane receptor expressed exclusively in cells of the myeloid 
lineage, especially microglia5,6. Upon ligand engagement, TREM2 activates downstream protein 
tyrosine phosphorylation through its adaptor DAP12/TYROBP and stimulates proliferation, 
phagocytosis, survival, and mTOR signaling7-13. While the exact ligands in the brain remain 
elusive and are likely to be context-dependent, TREM2 binds in vitro to apoptotic cells14, anionic 
ligands 9,15, apolipoproteins16-18, and amyloid-beta19. Cleavage of TREM2 by metalloproteinases 
releases soluble TREM220-22, which may mediate microglial cell survival and inflammation23,24. 
TREM2 studies in amyloid or tau mouse models have largely focused on mouse Trem2 
(mTrem2) deficiency. In amyloid mouse models, mTrem2 deficiency weakens the microglial 
response to amyloid plaques, impairs the microglial barrier, and worsens amyloid toxicity25-27. In 
tau mouse models, however, mTrem2 deficiency protects against tau-induced atrophy28,29, 
highlighting the complexity of the TREM2-mediated microglial response in AD brains. 
Little is known about how the R47H mutation contributes to AD. The prevailing 
hypothesis is that R47H causes only a partial loss-of-function. For instance, mTrem2 deficiency 
markedly reduces microglial coverage of amyloid plaques, whereas expression of R47H human 
TREM2 (R47H-hTREM2) has a much milder effect30. The R47H variant also causes subtler 
deficits in the shedding and maturation of soluble TREM2, protein stability, phagocytosis, and 
surface TREM2 expression21,31. Moreover, mTrem2 knockout macrophages have a more 
pronounced transcriptional response to reduced levels of CSF1 than homozygous R47H 
macrophages12. Of note, the R47H variant impairs ligand binding to a lesser extent than loss-of-
function mutations linked to Nasu-Hakola disease16-18. Indeed, human genetics also suggests 
that the loss-of-function effects of the R47H variant do not fully explain its role in AD, as 
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homozygous loss-of-function mutations in TREM2 cause Nasu-Hakola disease32, whereas 
homozygous R47H-TREM2 carriers develop AD33.  
Understanding the pathogenic mechanisms of R47H-TREM2 in AD is of critical 
importance for microglia-targeted therapeutic approaches. If R47H-TREM2 induces AD risk 
through loss-of-function, TREM2-enhancing therapies would be effective. Conversely, if R47H-
TREM2 induces AD risk through gain-of-toxic function, then those toxic pathways would need to 
be inhibited. In this study, we used CRISPR to knock-in WT or R47H-hTREM2 to replace one 
allele of mTrem2 in mice. Using a combination of behavioral, electrophysiological, and RNA-
sequencing approaches, we sought to dissect the disease-enhancing mechanisms of the R47H 
mutation. 
3.3 Results 
Heterozygous R47H-hTREM2 Induces Aberrant Hippocampal Synaptic Transmission and 
Impairs Spatial Memory 
Using CRISPR, we generated two knock-in mouse lines expressing one copy of WT 
(hTREM2WT/+) or R47H-hTREM2 (hTREM2R47H/+) cDNA in place of mTrem2 (Figure 1a). 
hTREM2WT/+ and hTREM2R47H/+ mice had equivalent levels of hTREM2 mRNA (Figure 1b) and 
protein (Figure 1c-d) and a dose-dependent reduction in mTrem2 mRNA levels (Figure 1e), 
indicating successful replacement of mTrem2 by hTREM2. The matched levels of WT and 
R47H-hTREM2 mRNA and protein allowed us to assess the consequences of the AD-
associated heterozygous R47H variant in vivo.   
We first examined whether a single allele of R47H-hTREM2 in mice causes hippocampal 
synaptic impairment. We performed field recordings in the molecular layer of the dentate gyrus 
while stimulating the perforant pathway in the hippocampus of 6.5- to 9-month-old mice. The 
synaptic response to increasing stimulus intensity was similar in hTREM2WT/+ and mTrem2+/+ 
(wild-type) controls, but was significantly greater in hTREM2R47H/+ mice (Figure 1f). Thus, 
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synaptic transmission in the perforant pathway was increased by the R47H mutation 
specifically, and not simply by the expression of human TREM2. The mutation did not affect the 
mean amplitude of the fiber volley, consistent with the lack of effect on action potentials 
generated by the presynaptic fibers (Figure 1g). Nor did it affect the sustained increase in the 
postsynaptic response upon induction of long-term potentiation (Figure 1h), highlighting the 
highly specific alterations induced by R47H-hTREM2 microglia on hippocampal circuitry.  
To examine effects of R47H-hTREM2 on spatial learning and memory, we tested 
mTrem2+/+, hTREM2WT/+, and hTREM2R47H/+ mice in a hippocampus-dependent assay, the 
Morris water maze. At 7 to 9 months of age, all three genotypes had similar latencies to reach 
the target quadrant during training (Figure 1i), indicating normal spatial learning. However, 
during the 24-hour probe trial, R47H-hTREM2 mice made more search errors (Figures 1j) and 
spent significantly less time in the target quadrant than wild-type mice (Figure 1k), indicating 
that R47H-hTREM2 microglia impair spatial memory. Interestingly, female hTREM2R47H/+ mice 
were significantly more impaired in spatial learning and memory than males (Supplementary 
Figure 1, a-f). The memory deficits were induced specifically by the R47H mutation, as 
hTREM2WT/+ and mTrem2+/+ mice performed identically regardless of sex (Supplementary 
Figure 1, g-l). 
To rule out hyperactivity and anxiety, which could confound the spatial memory test 
results, we examined the mice in the open field and elevated plus maze assays. hTREM2R47H/+, 
hTREM2WT/+, and Trem2+/+ mice did not differ in their activity levels in the open field 
(Supplementary Figure 2, a-d) nor in the percentage of time spent in the open arms of the 
elevated plus maze (Supplementary Figure 2, e-h). Taken together, our findings suggest that 
the hippocampal circuitry and spatial memory are particularly vulnerable in hTREM2R47H/+ mice. 
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R47H-hTREM2 Induces Unique Transcriptional Changes in Neurons and 
Oligodendrocytes  
To dissect how R47H induces functional deficits, we performed single-nuclei RNA-
sequencing (snRNA-seq) of mouse hippocampal tissue isolated from 9-month-old mTrem2+/+ 
and hTREM2R47H/+ female mice. We sequenced 33,178 nuclei and used 31,783 cells that 
passed stringent quality control, including total gene count, total molecule count, and the 
percentage of mitochondrial RNA (Supplementary Figure 3), for downstream analysis. 
Unsupervised clustering revealed 11 transcriptionally distinct populations that were categorized 
as 8 major cell lineages using known cell type marker genes34,35 (Figure 2a).  
Visualizing the data by genotype revealed no differences in the densities of the cell types 
between genotypes (Figure 2b). We did not see many alterations in microglial transcriptome and 
number with the R47H mutation (Figure 2, c-d). Immunohistochemical findings also confirmed 
similar microglial densities and morphologies in 8- to 9-month-old hTREM2WT/+ and 
hTREM2R47H/+ mice (Supplementary Figure 4, a-g). Microglial motility, using in vivo imaging29, 
also showed little difference at 12–17 months of age, regardless of hTREM2 mutation status. 
Baseline velocities of hTREM2WT/+ and hTREM2R47H/+ microglial processes were similar to those 
of mTrem2+/+controls, as were the responses to laser-induced injury (Supplementary Figure 4, 
h-j, Supplementary Movie 1). This finding was in contrast to our observation in mTrem2+/– 
microglia, which exhibited a marked impairment in response to laser-induced injury29, 
suggesting that the heterozygous R47H variant does not induce loss-of-function in the context 
of microglia’s response to acute tissue injury.   
Unlike microglia, neurons and oligodendrocytes showed dramatic changes in their 
transcriptional profiles (Figure 2d). Using Ingenuity pathway analysis, we identified the top 
upstream regulators for these cell types (Figure 2, e-g). Interestingly, the top two significantly 
activated upstream regulators across all three cell types modulate oxidative phosphorylation 
(CAB39L, HBA1/HAB2). The upstream regulator associated with the most significant decrease 
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in activity across all three cell types, RICTOR, modulates cell growth. Ingenuity pathway 
analysis of the differentially expressed genes (DEGs) in neurons and oligodendrocytes revealed 
a striking overlap in the top impacted pathways for each cell type (Figure 2h), in line with the 
overlap in upstream regulators. The most significantly enriched pathway in excitatory neurons, 
inhibitory neurons, and oligodendrocytes was oxidative phosphorylation (Figure 2h), suggesting 
altered cellular metabolism in these cell types. The other enriched pathways included EIF2, 
sirtuin, mTOR and synaptogenesis signaling pathways, highlighting the non-cell autonomous 
impact of R47H-hTREM2-expressing microglia.  
R47H-hTREM2 Exacerbates Spatial Learning and Memory Deficits and Inflammatory 
Responses in Female Tauopathy Mice 
The R47H variant significantly increases risk for AD, and cognitive deficits in AD 
correlate more strongly with tau load than with amyloid plaques36,37. To assess the effect of 
R47H-hTREM2 on tau pathology, we crossed hTREM2WT/+ and hTREM2R47H/+ mice with P301S 
mice, which express a mutant human tau gene and develop hallmarks of tauopathy, including 
gliosis, tau inclusions, and cognitive deficits38. At 7 to 9 months of age, when cognitive deficits 
manifest in P301S mice, the spatial learning curve of P301S hTREM2WT/+ mice did not differ 
from that of P301S mTrem2+/+ mice regardless of sex (Supplementary Figure 5), confirming 
again that WT-hTREM2 behaves identically to mTrem2. In contrast, R47H-hTREM2 significantly 
impaired spatial learning in female P301S mice, but had no effect in males (Figure 3, a–b). 
Female P301S hTREM2R47H/+ mice also made significantly more search errors during the 72-
hour probe trial than controls (Figure 3c). In contrast, male P301S hTREM2R47H/+ mice trended 
toward fewer search errors during the probe trial (Figure 3d). Overall activity (Supplementary 
Figure 6, a-d) and anxiety levels (Supplementary Figure 6, e-h) were unaltered by the R47H 
mutation in either sex, suggesting that spatial learning and memory are specifically impacted by 
R47H-hTREM2. 
	 61	
These sex-dependent behavioral deficits were also associated with sex-dependent 
pathological findings. Tauopathy is characterized by an accumulation of insoluble tau 
aggregates detectable with a confirmation-specific antibody, such as MC139. To directly 
compare the effects of R47H to WT hTREM2, we normalized tau loads to those of their 
respective P301S mTrem2+/+ (P301S) littermate controls. For confirmation-specific tau 
aggregates (MC1), P301S hTREM2R47H/+ males showed a modest trend toward increased MC1 
density, while females showed a trend toward decreased density in the cortex (Supplementary 
Figure 7, a-c, j-l). Inflammation and alterations in microglial morphology occur early in P301S 
mice38 and were also sex-dependent in R47H-hTREM2 mice. In males, there was a modest 
trend toward reduced microglial density in the cortex of P301S hTREM2R47H/+ mice compared to 
P301S hTREM2WT/+ mice (Supplementary Figure 7, d-f). Cell morphological analysis revealed 
that male P301S hTREM2R47H/+ microglia had significantly longer processes and significantly 
more branches (Supplementary Figure 7, g-i), indicating a more resting microglial state. In 
female P301S mice, R47H-hTREM2 significantly reduced the number of microglia in the cortex 
without affecting microglial density or morphology in the hippocampus (Supplementary Figure 8, 
m-r). Thus, R47H-hTREM2 also affected microglia and tau pathology in a sex-dependent 
manner, similar to the behavioral deficits. 
We next sought to identify potential molecular pathways underlying the sex-dependent 
effect of R47H-hTREM2 on tau-mediated learning and memory deficits. We performed bulk 
RNA-sequencing (RNA-seq) of the hippocampus from 7- to 9-month-old male and female 
P301S hTREM2R47H/+ mice and their littermate P301S mTrem2+/+ controls. Analyses of the 
DEGs revealed that R47H-hTREM2 induced significant transcriptomic changes in females, 
including upregulation of several disease-associated microglial (DAM) genes (e.g., Ccl6, 
Clec7a, Siglec5, Cd9, Cd63)40 and other inflammatory genes (e.g., Cxcl5, Ccl9), and 
downregulation of neuron-associated genes (e.g., Adora2a, Syt6, Serpina9, Penk) (Figure 3e). 
In contrast, R47H-hTREM2 induced few transcriptional changes in male P301S mice (Figure 
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3f), consistent with the lack of a significant effect of R47H-hTREM2 on cognitive deficits in male 
P301S mice (Figure 3b,d). To identify biological networks associated with the detrimental effects 
of the R47H variant, we performed weighted gene-correlation network analysis (WGCNA) of the 
transcriptomes of female P301S hTREM2WT/+ and P301S hTREM2R47H/+ mice and their P301S 
mTrem2+/+ littermate controls (Figure 3g). Two correlational modules exhibited statistically 
significant positive or negative correlations with the P301S hTREM2R47H/+ mice (Figure 3g). The 
positive (brown) module was significantly enriched in microglial genes (Figure 3h), namely 
transcripts encoding cytokines, cytokine receptors, and chemokines (e.g., Ccr5, Ccl5, Ccl3, 
Cxcl5) (Figure 3, i-j). The negative (cyan) module was significantly enriched in neuronal genes 
(Figure 3h), such as transcripts encoding axon guidance molecules (e.g., Sema6b, Sema3f, 
Epha8, Ephb6) (Figure 3i). This downregulation of hippocampal neuronal transcripts is 
consistent with the worsened spatial learning and memory observed in P301S hTREM2R47H/+ 
female mice.  
R47H-hTREM2 Increases the Disease-Associated Microglia Signature in Female 
Tauopathy Mice 
In AD mouse models with amyloid pathology, mTrem2 deficiency blocked expression of 
a subset of DAM genes40. Interestingly, some of these TREM2-dependent DAM genes were 
significantly upregulated in P301S hTREM2R47H/+ mice (e.g., Cd9, Clec7a, Ccl6) (Figure 3e), 
suggesting that the R47H mutation differs from the mTrem2 deficiency model. To further probe 
these microglial signatures, we turned to deep single-cell RNA-seq41. We sorted microglia from 
the hippocampal tissue of 8-month-old female mTrem2+/+, hTREM2R47H/+, P301S, and P301S 
hTREM2R47H/+ mice, gating on CD45lowCD11b+ (Supplementary Figure 8a). Out of the 1,480 
cells that were sorted, 1,424 passed quality control (Supplementary Figure 8, b-d). 
Unsupervised clustering of these 1,424 cells yielded two clusters (Figure 4a). While cluster 1 
microglia were found in all 4 genotypes, cluster 2 microglia were mainly found in the presence of 
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P301S (Figure 4b) and this population was further significantly enriched in P301S hTREM2R47H/+ 
mice (Figure 4c). A more detailed analysis of cluster 2 revealed that the most significantly 
upregulated transcripts included several DAM transcripts, such as Clec7a, Ctsb, Axl, Cst7, 
Apoe, and Cd63 (Figure 4d). While both cluster 1 and 2 expressed homeostatic microglial 
genes, such as P2ry12 and Hexb, DAM transcripts Apoe and Cst7 were mainly localized to 
cluster 2 (Figure 4e). Indeed, there was a statistically significant correlation between cluster 2 
DEGs and DAM transcripts, whereby all but four of the upregulated transcripts in cluster 2 were 
also upregulated in DAM (Figure 4f). Upregulation of Apoe in microglia was validated by 
RNAscope, whereby P301S hTREM2R47H/+ exhibited a significant increase in the percentage of 
ApoE+ C1qa+ cells in the dentate gyrus (Figure 4, g-i). In sum, R47H-hTREM2 expression in 
female tauopathy mice resulted in a significant increase in cluster 2 microglia, which were 
enriched for DAM-associated genes.  
 
R47H-hTREM2 Induces Unique Transcriptional Changes in Neurons and 
Oligodendrocytes in Female Tauopathy Mice 
To determine how these transcriptomic changes in hTREM2R47H/+ microglia affected 
other cell types in the brain in the context of tauopathy, we performed single-nuclei RNA-seq 
(snRNA-seq) of mouse hippocampal tissue isolated from 9-month-old P301S and P301S 
hTREM2R47H/+ female mice. We sequenced 33,178 nuclei and used 31,783 cells that passed 
quality control (Supplementary Figure 9) for downstream analysis. Unsupervised clustering 
revealed 11 transcriptionally distinct populations that were categorized as 8 major cell lineages 
using known cell type marker genes34,35 (Figure 5a). R47H-hTREM2 reduced the excitatory 
neuron cluster and expanded the oligodendrocyte cluster in female tauopathy mice (Figure 5, b–
c). Compared to the single-nuclei data in the absence of tauopathy (Figure 2), we found greater 
numbers of DEGs induced by R47H-hTREM2 across all cell types. However, similar to the data 
in the absence of tauopathy, we again found that neurons and oligodendrocytes had the 
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greatest number of DEGs (Figure 5d), suggesting that they are especially impacted by R47H-
hTREM2.  
Similar to what was observed in the absence of tauopathy, two of the top activated 
upstream regulators across excitatory neurons, inhibitory neurons, and oligodendrocytes were 
CAB39L and HBA1/HBA2, regulators of oxidative phosphorylation. Pathway analysis of the 
neuronal and oligodendrocyte DEGs showed similar changes in cellular pathways, with the 
exception of the mTOR signaling pathway which was upregulated in oligodendrocytes but 
downregulated in neurons (Figure 5h). Notably, sirtuin signaling oxidative phosphorylation 
showed the same directionality of change in nontransgenic and P301S mice in all cell types 
(Figure 2h, 5h). Altogether, these transcriptional changes highlight dysregulation of the oxidative 
phosphorylation pathway in neurons and oligodendrocytes in R47H-hTREM2 mice. 
   
R47H TREM2 Microglia Impact Metabolic Pathways in Oligodendrocytes in Human AD 
Brains 
Lastly, we dissected cell-type-specific molecular pathways induced by R47H-TREM2 
microglia in human AD and compared them with our R47H-TREM2 tauopathy mouse model. 
We performed snRNA-seq of frontal and temporal cortices from 3 AD brains, 3 R47H-AD brains, 
and 3 control brains from both men and women (Figure 6a). Using an established human 
snRNA-seq protocol35, we sequenced 111,185 nuclei and used 102,702 cells that passed 
quality control (Supplementary Figure 10, a-b). for downstream analysis. Using reference gene 
sets for cluster annotations42,43 (Supplementary Figure 10, c-d), we identified all the major cell 
types in the brain (Supplementary Figure 10e). Cells from frontal and temporal cortices 
contributed equally to all major cell types identified (Supplementary Figure 10f), with some 
variability across individuals in the proportion of cells in each cluster (Supplementary Figure 
10g).  
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Plotting the three patient populations on separate t-SNEs revealed a differential 
distribution of cells across the 7 major clusters (Figure 6b). Notably, similar to what we observed 
in our mouse model, neurons and oligodendrocytes had the greatest number of DEGs in R47H-
AD versus AD patients, with oligodendrocytes having close to 10,000 DEGs, 6,718 of which 
were upregulated (Figure 6c). To probe the transcriptional overlap between our mouse and 
human datasets, we focused on glial cells, as different neuronal populations were sampled 
between the mouse and human experiments. The greatest number of overlapping DEGs was in 
oligodendrocytes (Figure 6d). Ingenuity pathway analysis of the overlapping upregulated DEGs 
in oligodendrocytes highlighted the same pathways we observed in R47H-hTREM2 mice: EIF2, 
sirtuin, oxidative phosphorylation, and mTOR signaling, with mitochondrial dysfunction emerging 
as the most significantly enriched pathway, followed by oxidative phosphorylation (Figure 6e). 
Multiple components of the oxidative phosphorylation pathway were found in the overlapping 
dataset (Figure 6f), indicating that this pathway in oligodendrocytes is especially impacted by 
R47H-hTREM2. Overall, these findings indicate that oligodendrocytes are particularly affected 
by the R47H variant, and that the oligodendrocyte oxidative phosphorylation pathway altered by 
R47H appears to be conserved between our tauopathy mouse model and human patients.   
3.4 Discussion 
In this study, we generated hTREM2 knock-in mouse models with matched levels of WT 
and R47H hTREM2, which allowed us to model TREM2 R47H heterozygosity in mice to mimic 
human AD R47H carriers. We found that introduction of human TREM2 did not alter cellular 
transmission or behavior, as WT-hTREM2 mice behaved similarly to mTrem2+/+ mice in both the 
presence and absence of tau pathology. These findings suggest that human TREM2 behaves 
similarly to mouse Trem2. The heterozygous R47H mutation alone was sufficient to cause 
behavioral and synaptic deficits and exacerbate tau-mediated spatial learning and memory, but 
only in female mice. Notably, these sex-dependent effects of R47H-hTREM2 were associated 
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with sex-dependent transcriptomic changes. We also found that R47H-hTREM2 mice differed 
from Trem2 haploinsufficient mice in microglia’s response to injury, tau load, and global 
transcriptomics, which argues against the R47H variant as a pure loss-of-function mutation in 
the context of tauopathy. R47H-hTREM2 altered the transcriptome of many cell types in the 
brain of female tauopathy mice, causing increased expression of DAM genes in microglia, and 
mitochondrial changes in neurons and oligodendrocytes. The single-nuclei RNA-seq analyses of 
cortices from AD patients with and without the R47H mutation revealed multiple pathways in 
oligodendrocytes that were altered by R47H-hTREM2. Moreover, there was a significant 
correlation between human oligodendrocyte DEGs and those in our P301S hTREM2R47H/+ 
mouse model, underscoring the relevance of our new R47H-hTREM2 mouse model for the 
study of AD. 
 Our mouse model is unique in that the matched mRNA and protein levels of the WT and 
R47H human TREM2 mouse lines allow us to specifically interrogate the effect of the R47H 
variant, in the absence of any overexpression or splicing artifacts. Two other R47H mouse 
models exist to date: a BAC transgenic overexpressing the common or R47H human TREM2 
variant on a mouse Trem2 knockout background30, and a CRISPR approach that introduced the 
single nucleotide change in the endogenous mouse Trem2 gene44. The latter model resulted in 
a 42% reduction in mouse Trem2 mRNA levels due to alternative splicing that occurs in mouse, 
but not human tissue, with the R47H variant45. Both models were used to study R47H-hTREM2 
in the context of amyloid pathology. Overall in both models, R47H exhibited mild deficits with 
respect to microglial density and cell survival, and did not impact overall plaque load30,44. 
Similarly, we found subtle effects of R47H-hTREM2 on microglial density and tau pathology in 
our model.  
R47H-hTREM2 in microglia increased the size of the excitatory postsynaptic potentials 
evoked in the dentate granule cells and was associated with an enrichment of the 
synaptogenesis signaling pathway in excitatory neurons. The increase in EPSP slope could be 
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due to an increase in postsynaptic responsiveness or in the number of synapses. TREM2 
promotes synapse pruning during development, and mice lacking Trem2 exhibit an increased 
frequency of miniature excitatory postsynaptic potentials46. Therefore, it is conceivable that 
R47H-hTREM2 microglia could alter synaptic function by impairing TREM2’s role in synapse 
pruning.  
Using single-nuclei RNA-seq, we identified significant changes in neurons and 
oligodendrocytes in hTREM2R47H/+ mice in the absence of tau pathology. These pathways were 
also altered in P301S hTREM2R47H/+ mice, indicating that they may be key to understanding the 
pathogenicity of R47H-hTREM2. Oxidative phosphorylation was upregulated in 
oligodendrocytes and neurons from R47H-hTREM2 mice in the absence and presence of 
tauopathy, suggesting altered metabolism in these cell types. Indeed, CAB39L and 
HBA1/HBA2, the top predicted upstream regulators in neurons and oligodendrocytes with and 
without tauopathy, are regulators of mitochondrial genes. Altogether, these transcriptional 
changes, along with the aberrant hippocampal synaptic transmission observed in R47H-
hTREM2 mice, point to metabolism as a pathway that may be particularly vulnerable to R47H-
hTREM2 expression and warrant further investigation. 
Behaviorally, R47H-hTREM2 exacerbated spatial learning and memory deficits in 7- to 
9-month-old mice without affecting other cognitive domains, such as activity or anxiety levels. 
This finding is consistent with the vulnerability of hippocampal circuitry in AD patients. Curiously, 
R47H-hTREM2 exacerbated tau-mediated deficits in female mice only, accompanied by a trend 
toward a lower tau load. In contrast, male P301S hTREM2R47H/+ mice, which showed a trend 
toward improved performance on the water maze, had an increased tau load. This disconnect 
between tau load and behavioral performance has been observed before. For example, 
apolipoprotein E4 (ApoE4) exacerbated brain atrophy in P301S mice without increasing tau 
burden47, and DAP12/TYROBP deficiency protected against tau-induced cognitive deficits while 
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elevating levels of hyperphosphorylated tau48. Thus, insoluble tau inclusions should be used 
with caution as the only biomarker of disease progression in tauopathy. 
The sex-specific effects of R47H-hTREM2 on tau-mediated cognitive deficits correlated 
strongly with the sex-specific transcriptional changes in these mice. R47H-hTREM2 increased 
the DAM signature in female tauopathy mice, including Trem2-dependent DAM transcripts. This 
is distinct from mTrem2 deficiency which blocked the transition from stage 1 to stage 2 DAM40, 
suggesting that R47H may not be simply a loss-of-function variant. Moreover, R47H-hTREM2 
female tauopathy mice also exhibited an increase in inflammatory transcripts, which may 
contribute to the deficits observed in these mice.  
These sex-dependent differences may reflect differences in disease severity. Trem2 
deficiency appears to exert opposing effects on plaque load at early versus late stages of 
amyloid pathology27, and, male and female P301S mice of the same age differ in microgliosis 
level and tau load49. However, sex differences in our hTREM2R47H/+ mice were observed even in 
the absence of tau pathology, suggesting that the sex-dependent effects of R47H-hTREM2 
microglia do not depend on disease severity. 
An alternative explanation for the sex-specific effects of R47H-hTREM2 may be the 
differences between male and female microglial transcriptomes50-52. For example, ApoE4 
increases risk for late-onset sporadic AD to a greater extent in women53,54, and female ApoE4 
knock-in mice have spatial memory deficits not seen in males55. Microglia-derived ApoE is a 
major source of plaque-associated ApoE56, suggesting that sex-specific differences in microglia 
may impact the sex-dependent effect of ApoE4 in AD pathogenesis57. To our knowledge, sex-
specific effects of R47H on AD pathology and progression have not been reported. A thorough 
assessment of the possibility of sex differences induced by R47H-hTREM2 in human patients 
would require much larger sample sizes due to the rarity of this mutation. 
We observed a striking correlation between mouse and human DEGs identified through 
single-nuclei RNA-seq in the oligodendrocyte cluster, suggesting some conserved mechanisms 
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between mouse and human glial cells in response to R47H-hTREM2 in the presence of 
tauopathy. The most significantly enriched pathways in the overlap between mouse and human 
oligodendrocytes were mitochondrial dysfunction and oxidative phosphorylation, suggesting 
altered metabolism in oligodendrocytes. Trem2 has been reported to modulate microglial 
metabolism through mTOR signaling7, yet its impact on oligodendrocyte metabolism has not 
been investigated. Interestingly mTOR signaling is also impacted in oligodendrocytes and 
neurons in R47H-hTREM2 mice with and without tau. These novel findings warrant further 
investigation, as they can shed light on R47H-hTREM2’s non-cell autonomous effects that may 
contribute to its pathogenicity.  
Of note, all of our R47H-AD patients had at least one ApoE4 allele. How R47H-TREM2 
and the ApoE genotype might interact to affect microglial function is unknown; however, AD 
pathology occurs in R47H-carriers in the absence of the ApoE4 allele suggesting that the E4 
allele is not required for R47H’s association with AD58. Due to our modest number of samples 
from R47H-AD patients, further studies are needed to confirm and extend the human 
sequencing findings. 
The significant transcriptional correlation between our R47H tauopathy mouse model 
and the R47H-AD human carriers shows the strong relevance of our R47H knock-in mice as a 
model of human R47H-AD. Our findings also illustrate the causative role of microglia in driving 
AD pathogenesis. Indeed, a single mutation of a microglial gene had detrimental functional 
consequences associated with profound transcriptional changes in multiple cell types in the 
brain, especially in neurons and oligodendrocytes, in both the mouse and human brain regions 
we sampled. While the R47H mutation is rare, understanding how R47H causes pathogenicity 
can shed light on how microglial toxicity contributes to AD. By unraveling disease-enhancing 
properties of R47H-hTREM2 in mouse and human, our study opens new avenues for 
developing microglia-targeted AD therapies. 
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3.5 Methods 
Mice 
CRISPR/Cas9-mediated knock-in of wild-type or R47H human TREM2 cDNA in place of 
mTrem2 was done by injecting embryos with Cas9, short-guide RNA (sgRNA), and donor 
vectors (generated by PNA Bio). The human TREM2 cDNA sequence was flanked on each side 
by 1-kb homology arms for the mTrem2. The sequences are as follows: Trem2 targeted region 
5´CCTGCTGCTGATCACAGGTGGGA and sgRNA sequence (antisense) 
5´TCCCACCTGTGATCAGCAGCAGG. Potential off-target genes were identified with CRISPR 
off-target prediction software (http://www.crispor.tefor.net). There were no predicted off-targets 
for 1- or 2-basepair mismatches. WT hTREM2 and R47H hTREM2 lines were maintained 
independently and backcrossed to nontransgenic C57BL/6 mice for two to three generations, 
then crossed to Cx3cr1GFP/GFP or P301S mice. Cx3cr1GFP/GFP (https://www.jax.org/strain/005582) 
were crossed with WT or R47H hTREM2 knock-in lines to obtain Cx3cr1GFP/+hTREMR47H/+, 
Cx3cr1GFP/+hTREM2WT/+, and Cx3cr1GFP/+mTrem2+/+ littermates for both lines. P301S transgenic 
mice (https://www.jax.org/strain/008169) were crossed with WT or R47H human TREM2 knock-
in mice to generate P301S hTREM2R47H/+ and littermate P301S mTrem2+/+ mice, as well as 
P301S hTREM2WT/+ and littermate P301S mTrem2+/+ mice. Mice of both sexes were used, and 
analyses based on sex are included in the main and supplemental figures. Mice underwent 
behavioral testing at 7 to 9 months of age and had not been used for any other experiments. At 
8 to 9 months of age, the same mice were used for pathology and RNA-seq studies. Cx3cr1GFP/+ 
mice were studied at 12 to 17 months of age. For electrophysiology studies, mice were 6.5 to 9 
months old. All mouse protocols were approved by the Institutional Animal Care and Use 
Committee, University of California, San Francisco. 
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Human Postmortem Samples 
Tissues from the superior frontal gyrus and temporal cortices from brains of donors with 
AD and the R47H mutation, donors with AD but without the R47H mutation, and non-AD 
controls (n = 3 donors per group, 2 samples per donor, one from each cortical region) were 
used for single-nuclear RNA-sequencing, for a total of 18 samples. Additional information about 
the donors can be found in Supplemental Table 10. Samples were from the Queen Square 
Brain Bank for Neurological Disorders at the University of College London Institute for 
Neurology (courtesy of Professor John Hardy and laboratory manager Linda Parsons). The 
NHS Health Research Authority, London-Central Research Ethics Committee approved the 
study and confirmed that informed consent was obtained from all subjects, REC Ref: 
19/LO/0721, IRAS project ID: 246790. 
In Vivo Imaging 
For intravital imaging with two-photon microscopy, thinned-skull windows were made in 
12–17-month-old Cx3cr1GFP/+ hTREMR47H/+, Cx3cr1GFP/+ hTREM2WT/+, and Cx3cr1GFP/+ mTrem2+/+ 
as described previously 29. Briefly, mice were anesthetized, the skull was exposed, and a small 
area over the cortex was thinned manually and with a high-speed drill (K.1070 High Speed 
Rotary Micromotor drill; Foredom). Mice were fixed onto a custom-made head plate and imaged 
with an Ultima IV multiphoton microscope (Bruker) equipped with MaiTai DeepSee-eHP lasers 
(Spectra Physics) tuned to 920 nm for imaging and InSight X3 lasers (Spectra Physics) tuned to 
880 nm for ablation. Z-stacks of images were acquired every 3 min in 1-µm steps with a 25x 
water-immersion objective at 2.4 optical zoom. Extensions and retractions of processes during 
baseline recordings were manually traced with the mTrackJ plugin. The movement of microglial 
cells toward a laser ablation site was analyzed by normalizing the number of processes near the 
injury site at each time point to the overall microglial density at that time point. 
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Acute Slice Preparation 
Mice were anesthetized with isoflurane and decapitated. The brains were removed, 
placed in ice-cold dissection solution containing (in mM): 210 sucrose, 2.5 KCl, 1.25 NaH2PO4, 
25 NaHCO3, 7 glucose, 2 MgSO4, and 0.5 CaCl2 (gassed with 95% O2/5% CO2, pH ~7.4), and 
cut horizontally with a vibratome into 400-µm-thick slices in ice-cold dissection solution. The 
slices were warmed to 35°C for 1 hr in artificial cerebral spinal (ACSF) containing (in mM): 119 
NaCl, 2.5 KCl, 26.2 NaHCO3, 1 NaH2PO4, 11 glucose, 1.3 MgSO4, and 2.5 CaCl2 (gassed with 
95% O2/5% CO2, pH ~7.4. Slices were then kept at room temperature in oxygenated ACSF until 
recordings were made. 
Electrophysiology 
The brain was quickly removed from mice that were anesthetized with isoflurane before 
decapitation. It was placed in ice-cold dissection solution containing (in mM): 210 sucrose, 2.5 
KCl, 1.25 NaH2PO4, 25 NaHCO3, 7 glucose, 2 MgSO4, and 0.5 CaCl2 (gassed with 95% O2-
5% CO2, pH ~7.4). Horizontal brain slices (400 µm) were made on a vibratome in ice-cold 
dissection solution. Slices recovered for 1 hour in artificial cerebral spinal (ACSF) warmed to 
35°C containing (in mM): 119 NaCl, 2.5 KCl, 26.2 NaHCO3, 1 NaH2PO4, 11 glucose, 1.3 
MgSO4, and 2.5 CaCl2 (gassed with 95% O2-5% CO2, pH ~7.4). Then they were kept at room 
temperature in oxygenated ACSF. For recordings, slices were continuously perfused in ACSF at 
30°C. Perforant pathway inputs to the dentate gyrus were stimulated with a bipolar tungsten 
electrode (FHC, Bowdoin, ME). An ACSF-filled recording electrode (~3 MΩ pipette resistance) 
was placed ~50 µm into the molecular layer of the dorsal dentate gyrus. A Model 2100 Isolated 
Pulse Stimulator (A-M Systems) was used to generate stimuli every 30 s and responses to 10–
50 µA stimulus intensities were recorded with a 0.05-ms stimulus duration. LTP recordings were 
performed with picrotoxin (100 µM, Abcam), and the baseline stimulus intensity was set at 30% 
of the maximal fEPSP slope. Theta burst stimulation (TBS) was used to induce LTP, and the 
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stimulus intensity was set at 60% of the maximal fEPSP slope during TBS. Ten theta bursts 
were delivered every 15 sec, each consisting of 10 bursts of 4 100-Hz pulses every 200 ms. 
Behavioral Tests 
In all behavioral tests, hTREM2WT/+ and hTREM2R47H/+ mice were compared to their 
respective nontransgenic or P301S littermates. Experimenters were blinded to mouse 
genotypes throughout the experiments. Male and female mice were tested on separated days. 
Morris Water Maze. The water maze consists of a pool (122 cm in diameter) containing 
opaque water (20 ± 1°C) and a platform (10 cm in diameter) 1.5 cm below the surface. Three 
different images were posted on the walls of the room as spatial cues. Hidden platform training 
(days 1–7) consisted of 14 sessions (two per day, 2 hrs apart), each with two trials. The mouse 
was placed into the pool at alternating quadrants for each trial. A trial ended when the mouse 
located the platform or after 60 sec had elapsed. At 24 and 72 hrs after training, the mice were 
tested in probe trials, in which the hidden platform was removed and mice were allowed to swim 
for 60 sec. Mice received 7 days of hidden platform training before the 24-hr and 72-hr probe 
trials. Visible platform testing was done 24 hrs after the last probe trial. Performance was 
measured with an EthoVision video tracking system (Noldus Information Technology).  
Elevated Plus Maze. The maze consists of two 15 x 2-inch open arms without walls and 
two closed arms with walls 6.5 inches tall and is 30.5 inches above the ground. Mice were 
moved to the testing room 1 hr before testing to acclimate to the dim lighting. Mice were 
individually placed in the maze at the intersection of the open and closed arms and allowed to 
explore the maze for 10 min. 
Open Field. Mice were individually placed into brightly lit automated activity chambers 
equipped with rows of infrared photocells connected to a computer (San Diego Instruments). 
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Open field activity was recorded for 5 min. Recorded beam breaks were used to calculate total 
time of activity. 
Immunohistochemistry and Image Analysis 
Mice were transcardially perfused with phosphate-buffered saline (PBS). The brains were 
cut vertically into hemibrains. Half of each brain was flash frozen at –80°C for RNA-seq 
analyses; the other half was placed first in 4% paraformaldehyde for 48 hr and then in a 30% 
sucrose solution for 48 hr at 4°C and cut into 30-µm-thick sections with a freezing microtome 
(Leica). Free-floating sections (8–10 per mouse) were washed in PBS, placed in sodium citrate 
buffer for 30 min at 90°C for antigen retrieval, permeabilized with PBS containing 0.5% Triton X-
100 for 10 min, and blocked in PBS containing 10% normal goat serum for 1 hr. Sections were 
then placed in PBS with 5% normal goat serum and primary antibodies overnight at 4°C. The 
next day, sections were washed in PBS containing 0.1% Triton X-100, incubated with Alexa-
conjugated secondary antibodies in PBS with 5% normal goat serum and washed in PBS 
containing 0.1% Triton X-100. Images were acquired with a Keyence BZ-X700 microscope and 
a 10x objective. Immunoreactivity was quantified with ImageJ software (NIH). Antibodies used 
for staining were anti-MC1 (1:500, kind gift from Dr. Peter Davies) and anti-Iba1 (1:500, Wako). 
Secondary antibodies used for staining were donkey anti-mouse 488 and donkey anti-rabbit 546 
(both 1:500, ThermoFisher Scientific). 
For 3D reconstruction of microglia, line-scanning confocal images of hippocampal CA3 
region were obtained with a confocal microscope (LSM880, Carl Zeiss Microscopy, Thornwood, 
NY) and a 40x objective (1-µm focal plane intervals, one field of view per mouse). Images were 
examined by maximum intensity Z-projection and reconstructed in 3D with Imaris software. 
Branching morphological was analyzed using the “Filament Tracer” function. Experimenters 
were blinded to mouse genotype. Data from P301S hTREM2WT/+ and P301S hTREM2R47H/+ mice 
were normalized to data from their respective sex-specific P301S littermate controls. 
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Western Blot 
Mouse brains were homogenized in RIPA buffer containing 50 mM Tris, pH 7.5, 150 mM 
NaCl, 0.5% Nonidet P-40, 1 mM EDTA (ThermoFisher Scientific), 1 mM phenylmethyl sulfonyl 
fluoride, protease inhibitor cocktail (Millipore Sigma) and phosphatase inhibitor cocktail 
(Millipore Sigma). After sonication, brain lysates were centrifuged at 18,000 g at 4°C for 30 min. 
Supernatants were collected and protein concentrations were measured with the Pierce BCA 
Protein Assay Kit (ThermoFisher Scientific). The same amount of protein was loaded onto a 4–
12% SDS-PAGE gel (Invitrogen), transferred to nitrocellulose membranes (GE Healthcare), 
blocked with 5% milk, and immunoblotted in 2% milk. Bands in immunoblots were visualized by 
enhanced chemiluminescence (ThermoFisher Scientific) and quantified by densitometry with 
ImageJ (NIH). The antibody used for western blot was anti-TREM2 (1:500, Cell Signaling). 
Immunoreactivity was detected with goat anti-rabbit HRP (1:2000, Millipore Sigma). 
Isolation of Adult Microglia 
Adult microglia were isolated from 3- to 4-month-old mTrem2+/+, hTREM2R47H/+, and 
hTREM2R47H/R47H mice as described 29. Briefly, after perfusion, brains were chopped with a razor 
blade, incubated with 3% collagenase type 3 (Worthington), 3 U/ml dispase (Worthington) and 
DNase (Millipore Sigma) at 37°C, inactivated with 2.5 mM EDTA (ThermoFisher Scientific) and 
1% fetal bovine serum (FBS) (Invitrogen), filtered through a 70-µm filter, centrifuged at 300 g for 
5 min at 18°C and resuspended in fluorescence-activated cell sorting (FACS) buffer. Samples 
were incubated with myelin-removal beads (Miltenyi Biotec) for 15 min at 4°C, passed through a 
magnetic LD column (Miltenyi Biotec), centrifuged at 300 g for 10 min, and resuspended in 
FACS buffer. Cells were magnetically separated and sorted with CD11b beads (Miltenyi Biotec) 
and a magnetic MS column (Miltenyi Biotec). CD11b-positive cells were centrifuged at 300 g for 
10 min, and RNA was extracted for RNA-seq. 
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Isolation of Primary Microglia and in vitro Tau Fibril Stimulation Assay 
Cortices were harvested from postnatal day 3 pups. The meninges were removed, and 
the cortical tissue was finely chopped with a razor blade and digested in 0.25% trypsin with 
DNAse (Millipore Sigma) at 37°C for 25 min. Digestion was stopped with DMEM containing 10% 
FBS. The tissue was then triturated and, spun at 200 g for 5 min, and the pellet was 
resuspended in DMEM and 10% FBS and plated in T75 flasks that had been pre-coated with 
poly-D-lysine (Millipore Sigma) and rinsed with water. Mixed cultures were maintained in flasks 
for 10–11 days. The flasks were then shaken for 2 hr, spun at 200 g for 15 min, and the cells 
were plated at a density of 150,000/well. After 24 hr, cells were treated or not with 1ug of 0N4R 
tau fibril per well (from Dr. Jason Gestwicki) for approximately 16 hr before lysis for RNA 
isolation. 
RNA-Sequencing and Analysis of Bulk Hippocampal Tissue 
Hippocampal RNA was isolated with the Qiagen RNeasy Mini Ki. After quality control 
analysis with a Bioanalyzer, the RNA was sent to Novogene for library preparation and PE150 
sequencing with an Illumina HiSeq 4000 instrument. 48 samples were sent in for sequencing: 6 
samples each from male and female P301S WT and R47H hTREM2 knock-in mice and P301S 
mTrem2+/– mice, and 3 samples each for male and female P301S mTrem2+/+ littermates of the 
hTREM2WT/+ line and male and female P301S mTrem2+/+ littermates of the hTREM2R47H/+ line. 
Quality Control. We used multiple clustering methods to examine the quality of 
replicates and to identify possible outlier samples for exclusion if necessary. For the hTREM2 
R47H line (LG72), three samples were excluded from further analysis based on clustering. 
Clustering techniques were applied to variance stabilizing transformed expression values, 
fragments per kilobase of transcript per million mapped reads, and values of log counts per 
million. The Pearson correlation coefficient was first used as a distance metric between 
samples. Hierarchical cluster analysis was then applied to measure similarity between the 
	 77	
Pearson correlations. The hierarchical clustering algorithm was an iterative process. Each 
iteration joined the two most similar clusters (based on Pearson correlation) and computed the 
distance between remaining clusters, continuing until there is just a single cluster. The distances 
between clusters were computed at each stage using the complete linkage clustering method 
(see manual for R hclust function). 
Differential Expression Analysis. Differential gene expression was calculated with the 
R package DESeq259. Counts were normalized with the trimmed mean normalization method60. 
Genes with <15 counts across all samples were excluded from analysis. The false discovery 
rate (FDR) was calculated with the Benjamini-Hochberg method61. Gene network analyses of 
RNA-seq data were done with gene set enrichment analysis (GSEA)62; cell types were defined 
by the top 100 genes expressed by each CNS cell type 63. Pathway analysis was done with 
Gene Ontology (GO) biological processes64,65 and the Kyoto Encyclopedia of Genes and 
Genomes (KEGG)66. Networks were visualized with Cytoscape (version 3.6.1)67, the STRING 
database68, and perfuse force directed layout. 
Weighted Gene Co-expression Network Analysis. Weighted gene co-expression 
network analysis (WGCNA) was done on normalized expression data with the R package 
WGCNA v1.5169. The top 5000 most variable genes were used to create modules, and the soft-
thresholding power parameter was set to 14. The minimum module size was 30 genes, and 
modules with a module eigengene dissimilarity below 0.2 were merged, creating 14 modules of 
43–1361 genes each after removal of the module (gray) that contain genes that do not belong to 
any other module. KEGG and GO biological processes were used for pathway analysis as 
described above. 
RNA-Seq and Analysis of Adult Microglia 
RNA from adult microglia was extracted from mTrem2+/+ (n = 7), hTREM2R47H/+ (n = 6), 
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and hTREM2R47H/R47H (n = 7) mice with the Qiagen RNeasy Mini Kit. RNA concentration was 
determined with a NanoDrop, and RNA quality was measured with a Bioanalyzer and the 
Agilent RNA Pico Chip. Samples with an RNA integrity number >7 were considered of good 
quality and used for subsequent steps. Libraries were then prepared with the QuantSeq 3´ 
mRNA-Seq Library Prep Kit FWD for Illumina. Library quality was assessed with a Bioanalyzer 
and the Agilent High Sensitive DNA Chip. Individual library concentrations were measured with 
the Qubit dsDNA HS Assay Kit and submitted for SE50 sequencing on an Illumina HiSeq 4000. 
Quality control was done on base qualities and nucleotide composition of sequences. Alignment 
to the GRCm38.84 Mus musculus (mm10) refSeq (refFlat) reference gene annotation was done 
with the STAR spliced read aligner and default parameters. Differential gene expression 
analysis was done with the R package DESeq2. Counts were normalized with the trimmed 
mean normalization method. Genes with <15 counts across all samples were excluded from 
analysis. The FDR was calculated with the Benjamini-Hochberg method. Pathway analysis was 
done using Gene Set Enrichment Analysis referencing Gene Ontology Biological Processes 
dataset. Predicted upstream activators and inhibitors of the transcriptome were determined 
using Ingenuity Pathway Analysis software (Qiagen). 
Quantitative Reverse-Transcription PCR 
Flash-frozen cortices were thawed and homogenized with a 21G needle in RLT buffer 
with 1% β-mercaptoethanol. RNA was isolated with the RNeasy Mini-Kit (Qiagen), and the 
remaining DNA was removed by incubation with RNase-free DNase. Purified mRNA was then 
converted to cDNA with the iScript cDNA Synthesis Kit (Bio Rad). Quantitative RT-PCR was 
performed on the ABI 7900 HT sequence detector (Applied Biosystems) with PowerUp SYBR 
Green master mix (ThermoFisher Scientific). The average value of three replicates for each 
sample was expressed as a threshold cycle (Ct), the point at which the fluorescence signal 
starts to increase rapidly. Then, the difference (ΔCt) between Ct values for the transcript of 
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interest and for mouse GAPDH was calculated for each sample. The relative gene expression 
for each sample was calculated as 2–ΔCt. The following primers were used:  
Primer: Human TREM2 Fwd: CCGGCTGCTCATCTTACTCT 
Primer: Human TREM2 Rev: GGAGTCATAGGGGCAAGACA 
Primer: Mouse GAPDH Fwd: TGGCCTTCCGTGTTCCTAC 
Primer: Mouse GAPDH Rev: GAGTTGCTGTTGAAGTCGCA 
Isolation of Nuclei from Frozen Postmortem Human Brain Tissue 
The protocol for isolating nuclei from frozen postmortem brain tissue was adapted from a 
previous study35. All procedures were done on ice or at 4°C. In brief, postmortem brain tissue 
was placed in 700 µl of homogenization buffer consisting of 320 mM sucrose, 5 mM CaCl2, 3 
mM Mg(CH3COO)2, 10 mM Tris HCl, pH 7.8, 0.1 mM EDTA pH 8.0, 0.1% IGEPAL CA-630, 1 
mM ß-mercaptoethanol, and 0.4 U µl−1 recombinant RNase inhibitor (Clontech) and 
homogenized with a Wheaton Dounce tissue grinder (15 strokes with the loose pestle). The 
homogenized tissue was filtered through a 40-µm cell strainer, mixed with an equal volume of 
working solution (83% OptiPrep density gradient medium [Sigma-Aldrich], 5 mM CaCl2, 3 mM 
Mg(CH3COO)2, 10 mM Tris HCl, pH 7.8, 0.1 mM EDTA pH 8.0, and 1 mM b-mercaptoethanol) 
and loaded on top of a two-layer OptiPrep density gradient: 750 ul of 30% OptiPrep solution 
(30% OptiPrep density gradient medium, 134 mM sucrose, 5 mM CaCl2, 3 mM Mg(CH3COO)2, 
10 mM Tris HCl, pH 7.8, 0.1 mM EDTA, pH 8.0, 1 mM ß-mercaptoethanol, 0.04% IGEPAL CA-
630, and 0.17 U µl−1 recombinant RNase inhibitor), which was on top of 300 ul of 40% OptiPrep 
solution (40% OptiPrep density gradient medium, 96 mM sucrose, 5 mM CaCl2, 3 mM 
Mg(CH3COO)2, 10 mM Tris HCl, pH 7.8, 0.1 mM EDTA, pH 8.0, 1 mM ß-mercaptoethanol, 
0.03% IGEPAL CA-630, and 0.12 U µl−1 recombinant RNase inhibitor). The nuclei were 
separated by centrifugation at 10,000 g for 5 min at 4°C. A total of 100 ul of nuclei was collected 
from the 30%/40% interface and washed with 1 ml of PBS containing 0.04% BSA. The nuclei 
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were centrifuged at 300 g for 3 min at 4°C and washed with 1 ml of PBS containing 0.04% BSA. 
Then the nuclei were centrifuged at 300 g for 3 min at 4°C and re-suspended in 100 µl of PBS 
containing 0.04% BSA. The nuclei were counted and diluted to a concentration of 1000 nuclei 
per microliter in PBS containing 0.04% BSA. 
Droplet-based Single-nuclei RNA-seq of Human Brain Tissue 
For droplet-based snRNA-seq, libraries were prepared with Chromium Single Cell 3’ 
Reagent Kits v3 (10x Genomics) according to the manufacturer’s protocol. The snRNA-seq 
libraries were sequenced with NextSeq 500/550 High Output v2.5 kits (150 cycles). 
Analysis of Droplet-Based Single-nuclei RNA-seq Data from Human Brain Tissue 
Gene counts were obtained by aligning reads to the hg38 genome with Cell Ranger 
software (v.3.0.0) (10x Genomics). To account for unspliced nuclear transcripts, reads mapping 
to pre-mRNA were counted. After quantification of pre-mRNA with the Cell Ranger count 
pipeline, the Cell Ranger aggr pipeline was used to aggregate all libraries (without equalizing 
the read depth between groups) to generate a gene-count matrix. Cell Ranger 3.0 default 
parameters were used to call cell barcodes. To remove doublets and poor-quality cells, cells 
were excluded from analysis if they were extreme outliers (observations outside the range [Q1 – 
k(Q3 – Q1),Q3 + k(Q3-Q1)], with k = 3 and Q1 and Q3 as the lower and upper quartiles) in 
terms of the number of genes, the number of unique molecular identifiers (UMIs), and the 
percentage of mitochondrial genes. Specifically, cells with unique molecular identifier (UMI) 
counts above 5400 were removed, cells with less than 300 and more than 3200 genes were 
removed, and cells with more than 5% mitochondrial genes were removed.  
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Cell Clustering, Differential Expression Analysis, and Gene Set Enrichment Analysis of 
Human Brain Tissue 
Normalization and clustering were done with the Seurat package70. In brief, counts for all 
nuclei were scaled by the total library size multiplied by a scale factor (10,000), and transformed 
to log space. A set of 2000 highly variable genes were identified with SCTransform from 
sctransform R package in the variable stabilization mode. This returned a corrected unique 
molecular identifiers (UMI) count matrix, a log-transformed data matrix, and Pearson residuals 
from the regularized negative binomial regression model. Principal component analysis (PCA) 
was done on all genes, and t-SNE was run on the top 23 PCs. Cell clusters were identified with 
the Seurat functions FindNeighbors (using the top 23 PCs) and FindClusters (resolution = 0.02). 
For each cluster, we assigned a cell-type label using statistical enrichment for sets of marker 
genes42,43 and manual evaluation of gene expression for small sets of known marker genes. 
Enrichment was statistically assessed with the hypergeometric distribution (Fisher’s exact test) 
using the R package GeneOverlap and multiple hypothesis correction over all marker gene sets 
and clusters. The differential gene expression analysis was done with the Wilcoxon rank-sum 
test and FDR multiple-testing corrections as implemented in the Seurat function FindMarkers. 
Gene set enrichment analysis to assess the overlap of human and mouse DEGs were done with 
the hypergeometric distribution (Fisher’s exact test) as implemented in the R package 
GeneOverlap and with multiple hypothesis correction over all gene sets. 
Isolation of Nuclei from Frozen Mouse Tissue for Single-nuclei RNA-seq 
All steps were done on water-ice. The brain samples were chopped into pea-size pieces 
and transferred to a Dounce homogenizer (Sigma cat no. D8938) containing 2 ml of nuclei pure 
lysis buffer (Millipore Sigma, cat no. L9286). They were then homogenized by 20–25 strokes of 
a large clearance pestle and then with 20 strokes of a small clearance pestle. The resulting 
suspension was first filtered through the 70-µm mesh cap of a 5-ml Falcon tube (Corning) and 
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then through 35 µm mesh Cell Strainer Snap Cap, and collected to a 2.0-ml Eppendorf 
LoProtein binding tube. To confirm the quality of dissociated nuclei, 10 µl of the nuclei 
suspension was mixed with 10 µl of 0.5% (w/v) Trypan Blue and 1 µl of 20x DAPI dye and 
examined under bright-field and fluorescence microscope.  
The remaining suspension was centrifuged at 600 g for 5 min at 4ºC in a swinging 
bucket centrifuge. The pellet was re-suspended in 1 ml of freshly prepared ice-cold nuclei wash 
buffer (1x PBS, 20 mM DTT, 1% (w/v) BSA, 0.2 U/µl RNAse Inhibitor (Ambion), DEPC-treated 
water), and passed through 35-µm mesh cap. To confirm the quality and number of single 
nuclei, 10 µl of the nuclei suspension was mixed with 10 µl of 0.5% (w/v) Trypan Blue dye and 
examined with a bright-field microscope. The suspension was considered high quality if it had 
isolated single DAPI+ nuclei with uniform round morphology. We excluded suspensions with 
nuclei that appeared to be clumped together or if the suspension had over 10% of nuclei with a 
breaking, elongated shape.  The yield was ~106 single nuclei per 1 ml. Next, 50 µl of the nuclei 
suspension was diluted with 250 µl of nuclei wash buffer to be used as a negative reference for 
FACS. The remaining 900-950 µl of the suspension was stained with 10 µl of 100x DAPI dye 
and sorted on Aria III FACS instrument. Individual DAPI-positive nuclei were FACS sorted into 
collection tubes containing 1 ml of nuclei wash buffer. After FACS, nuclei were concentrated by 
centrifugation at 600 g for 5 min. The pellet was gently resuspended in ice-cold 1x PBS + 0.04% 
(w/v) BSA to achieve 2000 nuclei/µl. Finally, the single nuclei suspension was encapsulated and 
barcoded using 10x Genomics Chromium instrument. 
Droplet-based Single-nuclei RNA-seq of Mouse Brain Tissue 
The FACS-sorted suspension of DAPI-stained nuclei were washed once in ice-cold 1x 
PBS and 0.04% (w/v) BSA and loaded to microfluidic droplets with reagents provided in the 
Single Cell 3′ Reagents kit v2 (10x Genomics). mRNA barcoding was done at 53°C for 45 min, 
followed by heat inactivation at 85°C for 5 min. The barcoded-cDNA was PCR-amplified and 
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prepared for sequencing according to the Single Cell 3′ Reagent kit v2 User Guide (CG00052; 
Rev D). Next-generation sequencing was done on an Illumina NovaSeq 4000 instrument, using 
paired-end reads (R1 - 26 reads; R2 - 98 reads and index - 8 reads). FASTQ files containing the 
transcriptome and barcoding metadata were de-multiplexed with the SEQC pipeline71. In total, 
33,178 individual nuclei were identified after sequencing and data filtering; an average of 1082–
1759 UMIs per nucleus and 845–1194 genes per nucleus being detected. Sequencing depth 
was 2.59-6.76 reads per UMI. 
Analysis of Droplet-based Single-nuclei RNA-seq of Mouse Brain Tissue 
Preprocessing. The count matrix of all samples from 8 female mice (2 wild-type, 2 
hTREM2R47H/+, 2 P301S, and 2 P301S hTREM2R47H/+) were pooled and normalized with a 
regularized negative binomial regression model implemented in sctransform R package 
(Hafemeister and Satija, 2019, bioRxiv). Cells with more than 300 detected genes were retained 
for downstream analysis. Other QC including mitochondrial count ratio and cell cycle effects 
were examined as well. We used the Seurat v.3.070 R package to analyze the data. After the 
preprocessing step, we retrieved 31,783 single cells out of 33,178 sequenced with 17,269 
detected genes. We then identified a set of 3000 highly variable genes using the SCTransform 
from sctransform R package with the variable stabilization mode. This process returned a 
corrected unique molecular identifiers (UMI) count matrix, a log-transformed data matrix and 
Pearson residuals from the regularized negative binomial regression model. We then used 
RunPCA for principal component (PC) analysis of the Pearson residuals of the 3000 highly 
variable genes retained from previous steps. PCs were visually examined, and the first 20 PCs 
were selected for downstream clustering and dimensionality reduction analysis based off of the 
observed PC “elbow” using the PCElbowPlot function.  
Dimensionality Reduction and Clustering. We selected first 20 PCs and used the 
tSNE72 dimensionality reduction algorithm RuntSNE. For clustering of the first 20 PCs, we used 
	 84	
the modularity-based shared nearest neighbor clustering algorithm in Seurat’s FindClusters with 
resolution=0.2 and other default parameters. We retrieved 11 distinct cell clusters that 
encompassed 8 major cell types: astrocytes, excitatory neurons, inhibitory neurons, microglia, 
oligodendrocytes, oligodendrocyte precursor cells (OPCs), endothelial cells, and T cells. Cluster 
annotation was done manually by using established marker genes: SLC17A7, CAMK2A, NRGN 
(excitatory neurons), GAD1, GAD2 (inhibitory neurons), PLP1, MBP, MOBP (oligodendrocytes), 
SCRG1, PDGFRA, OLIG1 (OPCs), VTN, MGP, IGFBP7 (endothelial cells), C1QA, TYROBP, 
HEXB (microglia), CLU, ALDOC, PLA2G7 (astrocytes), and CD3D, CD3G, CCL5 (T 
lymphocytes). The significance of differences in the proportions of P301S and P301S 
hTREM2R47H/+ cells in each cluster was determined by chi-square test. 
Differential Expression Analysis. For differential expression analysis of cells 
annotated as “microglia”, we used the Wilcoxon rank-sum test implemented with the “wilcox” 
method in Seurat’s FindAllMarkers function. To identify DEGs among the 6 identified microglia 
clusters, we used the parameters min.pct=0.25 and logfc.threshold=0.25, which considered only 
genes that were detected in at least 25% of the cells in a given cluster and had at least 0.25-fold 
difference (~1.25 times) in expression level. 
Preparation of Mouse Hippocampus for Single-cell RNA-seq 
Brain tissue was prepared using a previously published protocol41. Briefly, 8-month-old 
female mice were anesthetized with avertin and transcardially perfused with phosphate-buffered 
saline (PBS). The brain without the cerebellum was harvested and collected into cold media 
with 15mM HEPES, 0.5% glucose in 1XHBSS without phenol red on ice. The entire procedure 
was done on ice. The hippocampus was extracted and chopped into pieces using a razor blade 
then further homogenized using a 2ml douncer containing 2ml medium A with 80uL DNase 
(12500 units/mL) and 5ul recombinant RNase inhibitor (Takara Bio 2313B). Homogenized tissue 
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was filtered through a 70um strainers to obtain a single cell suspension. Cells were washed with 
medium A and resuspended in 850uL MACS buffer with 1.8uL RNase inhibitor (sterile-filtered 
0.5% BSA, 2mM EDTA in 1 X PBS). Cells were incubated with 100uL myelin removal beads 
(MACS Miltenyl Biotec) for 10 min, and loaded onto LD columns (Miltenyi Biotec). Cells were 
collected and washed for FACS staining. 
Single Cell Sorting for Single-cell RNA-seq 
Cells were blocked in 5uL mouse Fc block for 5 min on ice then incubated with primary 
antibodies for 10 min then washed with FACS buffer (sterile-filtered 1% FCS, 2mM EDTA, 
25mM HEPES in 1XPBS). Cells were incubated with secondary antibodies for 10min then 
washed with FACS buffer. Cells were resuspended in 500uL FACS buffer with RNase inhibitor 
(Takara Bio 2313B, 1:500) and 0.5ul Propidium Iodide (ThermoFisher Scientific P3566, 1:1000) 
for single cell index sorting. Cell sorting/flow cytometry analysis was done on the cell sorter (BD 
InFlux) at the Stanford FACS Facility. The following gates were used for sorting microglia: (1) 
forward scatter-area (FSC-A)/side scatter-area (SSC-A) (2) Trigger Pulse Width/ FSC (3) Live- 
Dead negative using PI (4) CD45lowCD11b+ and CD45hiCD11b+. Single cells were sorted into 
96-well plates containing 4uL lysis buffer containing 4U Recombinant RNase Inhibitor (Takara 
Bio 2313B), 0.05% Triton X-100, 2.5mM dNTP mix (ThermoFisher Scientific R0192), 2.5uM 
Oligo-dT30VN (50-AAGCAGTGGTATCAACGCAGAGTACT30VN-30), and ERCC Spike-ins 
(ThermoFisher Scientific 4456740) diluted at 1:2.4x107. Plates were vortexed, spun down and 
frozen on dry ice, and plates were stored at −80°C freezer. Antibodies used for FACS: rabbit 
anti-mouse Tmem119 (Abcam ab210405, ~200ug/ul, 1:400 dilution), CD45-PE-Cy7 
(ThermoFisher Scientific 25-0451-82, 1:300), CD11b-BV421 (BioLegend 101236, 1:300), goat 
anti-rabbit Alexa 488 (ThermoFisher Scientific 11034, 1:300).  
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Single-cell RNA-seq library preparation 
Sequencing libraries were prepared following the Smart-seq2 published protocol73. 
Briefly, plates were thawed and incubated at 72°C for 3 min in order to anneal RNAs to the 
Oligo-dT30VN primer. The 6uL of the reverse transcription mixture was added to each well: 95U 
SMARTScribe Reverse Transcriptase (100U/µl, Clontech 639538), 10U RNase inhibitor 
(40U/µl), 1XFirst-Strand buffer, 5mM DTT, 1M Betaine, 6mM MgCl2, 1µM TSO (Exiqon, Rnase 
free HPLC purified). RT was performed at 42°C for 90 min, followed by 70°C, 5 min. 15ul of 
PCR amplification mix containing the following reagents was added to each well: 1X KAPA HIFI 
Hotstart Master Mix (Kapa Biosciences KK2602), 0.1uM ISPCR Oligo (AAGCAGTGGTAT 
CAACGCAGAGT), 0.56U Lambda Exonuclease (5U/ul, New England BioLabs M0262S). cDNA 
was amplified using the following PCR program: (1) 37°C 30 min; (2) 95°C 3 min; (3) 23 cycles 
of 98°C 20 s, 67°C 15 s, 72°C 4 min; (4) 72°C 5 min. cDNA samples were purified using 
PCRClean DX beads (0.7:1 ratio, Aline C-1003-50), and resuspended in 20ul EB buffer. cDNA 
quality was examined with a Fragment Analyzer (AATI, High Sensitivity NGS Fragment Analysis 
Kit:1 bp - 6000 bp). To make libraries, all samples were diluted down to 0.15ng/ul in 384-well 
plates using Mantis Liquid Handler (Formulatrix) and Mosquito X1 (TTP Labtech) with 
customized scripts. Nextera XT DNA Sample Prep Kit (Illumina FC-131-1096) was used at 1/10 
of recommendation volume, with the help of a Mosquito HTS robot for liquid transfer. 
Tagmentation was done in 1.6ul (1.2ul Tagment enzyme mix, 0.4ul diluted cDNA) at 55°C, 10 
min. 0.4ul Neutralization buffer was added to each well and incubated at room temperature for 5 
min. 0.8ul Illumina Nextera XT 384 Indexes (0.4ul each, 5uM from 4 sets of 96 indexes) and 
1.2ul PCR master mix were added to amplify whole transcriptomes using the following PCR 
program: (1) 72°C 3 min; (2) 95°C 30 s; (3) 10 cycles of 95°C 10 s, 55°C 30 s, 72°C 1 min; (4) 
72°C 5 min. Libraries from one 384 plate were pooled into an Eppendorf tube and purified twice 
using PCRClean DX beads. Quality and concentrations of the final libraries were measured with 
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Bioanalyzer and Qubit, respectively. Libraries were sequences on the Illumina HiSeq 4000 at 
the Weill Cornell Medicine Genomics and Epigenomics Core Facility.  
Processing of Single-cell RNA-seq Raw Data  
Prinseq74 was first used to filter sequencing reads shorter than 30 bp (-min_len 30), to 
trim the first 10 bp at the 50 end (-trim_left 10) of the reads, to trim reads with low quality from 
the 30 end (-trim_qual_right 25) and to remove low complexity reads (-lc_method entropy, -
lc_threshold 65). Then, Trim Galore was applied to trim the Nextera adapters (–stringency 1). 
The remaining reads were aligned to the mm10 genome by calling STAR (Dobin et al., 2013) 
with the following options: –outFilterType BySJout,–outFilterMultimapNmax 20,–
alignSJoverhangMin 8,–alignSJDBoverhangMin 1,– outFilterMismatchNmax 999,–
outFilterMismatchNoverLmax 0.04,–alignIntronMin 20,–alignIntronMax 1000000,– 
alignMatesGapMax 1000000,–outSAMstrandField intronMotif. Picard was then used to remove 
the duplicate reads (VALIDATION_ STRINGENCY = LENIENT, REMOVE_DUPLICATES = 
true). Finally, the aligned reads were converted to counts for each gene by using HTSeq (-m 
intersection-nonempty, -s no)75. 
Quality Control for Single-cell RNA-seq Data  
We used the following criteria to filter out cells with low sequencing quality. The 
distribution of total reads (in logarithmic scale) was fitted by a truncated Cauchy distribution, and 
data points in two tails of the estimated distribution were considered as outliers and eliminated. 
Fitting and elimination were then applied to the remaining data. This process was run iteratively 
until the estimated distribution became stable. The threshold was set to the value where the 
cumulative distribution function of the estimated distribution reaches 0.05. Cells with small 
numbers of detected genes and poor correlation coefficients for ERCC (low sequencing 
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accuracy) were dropped. 1424 cells were retained for downstream analysis after filtering from 
1480 cells.  
Clustering Analysis of Single-cell RNA-seq Data  
The Seurat R package was used to perform unsupervised clustering analysis on the 
filtered scRNA-seq data70,76. Gene counts were normalized to the total expression and log-
transformed. Principal component analysis was performed on the scaled data using highly 
variable genes as input. The JackStrawPlot function was used to determine the statistically 
significant principal components. These principal components were used to compute the 
distance metric and generate cell clusters. Non-linear dimensional reduction (t-SNE) was used 
to visualize clustering results. Differentially expressed genes were found using the 
FindAllMarkers function that ran Wilcoxon rank sum tests.  
Quantification and Statistical Analysis 
Data were analyzed with Graphpad Prism v.7, STATA12, or R. A multilevel mixed-
effects linear regression model fitted with STATA12 was used to compare the response to injury 
of aged mice and analyze latency in the Morris water maze. R was used to calculate the area 
under the curve for cumulative search errors in the Morris water maze. Outliers were removed 
with Prism’s outlier analysis algorithm. All statistical details can be found in the figures and 
figure legends. P < 0.05 and FRD < 0.05 was considered statistically significant, unless 
otherwise noted. All values are expressed as mean ± SEM, unless otherwise noted. A subset of 
mice from the behavior cohort was randomly selected for single-nuclei RNA-seq and bulk RNA-
seq studies. 
Data Availability 
All RNA sequencing data will be deposited in the Gene Expression Omnibus (GEO). 
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3.8 Main Figures	
	
Figure 3.1 R47H-hTREM2 Induces Aberrant Synaptic Transmission and Spatial Memory 
Impairment.  
a, The human TREM2 donor vector was designed with two 1-kilobase long arms homologous 
to mouse Trem2 flanking the wild-type or R47H human TREM2 cDNA sequence. When 
inserted into the genome, hTREM2 cDNA is driven by the endogenous mouse Trem2 
promoter. 
b, Quantitative real-time PCR analysis of cortical tissue from 3-4-month-old mice for human 
TREM2 mRNA. Samples were run in triplicate, and averages of the three wells were used for 
quantification, normalized to GAPDH. Puncta represent the average of three wells from one 
mouse. Two-tailed Mann-Whitney U-test comparing WT/+ and R47H/+. 
c, RIPA-soluble cortical lysates from 8-9-month-old mice were immunoblotted for human 
TREM2 and actin. Lane 1=mTrem2 KO, Lanes 2-3=mTrem2+/+ 
d, Ratio of hTREM2/actin from western blot in (c). Student’s two-tailed t-test.  
e, RNA-sequencing of adult microglia isolated from 3-4-month-old mice. Mouse Trem2 
(mTrem2) transcript levels decreased as human TREM2 levels increased. FPKM, fragments 
per kilobase of transcript per million mapped reads. Kruskal-Wallis statistic=16.01, p=1.289e-
007, Kruskal-Wallis test with Dunn’s post-hoc analysis.  
f-h, Field recordings in the molecular layer of the dentate gyrus in response to stimulation of 
the perforant pathway in 6.5–9-month-old mice (n=12–13 slices from 4 mice/genotype). f, 
Mean field excitatory postsynaptic potential (fEPSP) slope calculated at increasing stimulus 
intensities. hTREM2R47H/+ slices had significantly larger synaptic responses to stronger 
stimulus intensities compared to mTrem2+/+ slices. F=2.529 (genotype x stimulus), p<0.013, 
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*t=2.299, p=0.049 (30uA), *t=2.402, p=0.038 (40uA), **t=3.136, p=0.005, two-way repeated-
measures ANOVA with Bonferroni post-hoc analysis. g, Mean amplitude of the fiber volley 
(FV) was unaffected in hTREM2R47H/+ slices. Two-way repeated-measures ANOVA with 
Bonferroni post-hoc analysis. h, Mean fEPSP slope during long-term potentiation (LTP) 
induced by theta-burst stimulation of the perforant pathway in dentate granule cells. LTP in 
hTREM2R47H/+ mice was similar to that of mTrem2+/+ mice (n = 8 slices from 3 mice/genotype). 
Two-way repeated-measures ANOVA with Bonferroni post-hoc analysis for data between 75-
80 minutes. 
i-k, Spatial learning and memory assessment of 7–9-month-old mice using the Morris water 
maze. i, Latency to reach the platform location did not differ by genotype during hidden (d1–
d7) or visible platform trials (vd1–vd2). STATA mixed-effects modeling. j, (left) Cumulative 
search errors during the 24-hr probe trial were significantly greater in hTREM2R47H/+ mice than 
in nontransgenic littermates or hTREM2WT/+ mice. *Kruskal-Wallis statistic=7.671, p=0.0216, 
*t=2.615, p=0.02675 (mTrem2+/+ vs. hTREM2 R47H/+), *t=2.415, p=0.04723 (hTREM2 WT/+ 
vs. hTREM2 R47H/+), Kruskal-Wallis test with Dunn’s post-hoc analysis on area under the 
curve. (right) Representative search tracks from one mouse of each genotype. The blue 
square indicates the hidden platform location in the upper left-hand quadrant. The four 
quadrants of the pool are delineated by dashed lines. k, Percentage of time spent in the target 
quadrants during the 24-hr probe trial. hTREM2R47H/+ spent significantly less time in the target 
quadrant than mTrem2+/+ and hTREM2WT/+ mice. *F=3.462, p=0.03699, *t=2.581, p=0.02404, 
one-way ANOVA with Bonferroni post-hoc analysis. Data represent the combination of two 
behavioral cohorts that were run independently.  
Values are mean ± SEM. See also Supplementary Figures 1-2. 
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Figure 3.2 Microglial hTREM2-R47H Induces Unique Transcriptional States in Neurons 
and Oligodendrocytes  
a, t-SNE plots of all single nuclei and their annotated cell types from 2 each of mTrem2+/+ and 
hTREM2R47H/+ 9-month-old female mice. 
b, t-SNE plot split by genotype. 
c, Proportion of each cell type for each genotype. 
d, Total number of DEGs for each cell type for hTREM2R47H/+ vs. mTrem2+/+. FDR < 0.05. 
e-g, Ingenuity pathway analysis’s predicted upstream regulators for oligodendrocytes (e), 
excitatory neurons (f), and inhibitory neurons (g). Red and blue denote upstream regulators that 
are predicted to be activated or inhibited, respectively.   
h, Ingenuity canonical pathway enrichment analysis of DEGs in hTREM2R47H/+ vs. mTrem2+/+ by 
specified cell type. See also Supplementary Figures 3-4. 
Figure 2. Microglial R47H-hTREM2 Induces Transcriptional Changes in Neurons 
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Figure 3.3 R47H-hTREM2 Exacerbates Tau-Induced Spatial Learning and Memory 
Deficits in Females Only 
Spatial learning and memory assessment of 7–9-month-old mice using the Morris water 
maze.  
a-b, Latency to reach the platform during hidden trials (d1-d7) was significantly greater in 
female P301S hTREM2R47H/+ mice than in P301S littermates (a), but did not differ between 
male P301S hTREM2R47H/+ mice and P301S littermates (b). **p=0.003, STATA mixed-effects 
modeling. 
c-d, Cumulative search error was significantly greater in female P301S hTREM2R47H/+ mice 
than in P301S littermates (c), but did not significantly differ between male P301S 
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hTREM2R47H/+ mice and P301S littermates (d). *U=9, p=0.0164, two-tailed Mann-Whitney U-
test of area under the curve. A representative search track is shown for each genotype. The 
black square indicates the platform location in the upper left quadrant. The four quadrants of 
the pool are delineated by dashed lines. 
e, Volcano plot of RNA-sequencing data from bulk hippocampal tissue from 8–9-month-old 
female P301S hTREM2R47H/+ mice and line-specific female P301S controls. Blue dots are 
genes with significantly higher normalized counts in P301S controls than in P301S 
hTREM2R47H/+ samples (28 mRNAs). Red dots are genes with significantly higher normalized 
counts in P301S hTREM2R47H/+ samples than P301S controls (94 mRNAs). Genes in red are 
disease-associated microglial (DAM) genes and genes involved in inflammation. Genes in 
blue are genes associated with neuronal function. (n = 3 mice for P301S; n = 5 mice for 
P301S hTREM2R47H/+).  
f, Volcano plot of RNA-sequencing data from bulk hippocampal tissue from male P301S 
hTREM2R47H/+ and line-specific male P301S controls. Blue dots are genes with significantly 
higher normalized counts in P301S controls than P301S hTREM2R47H/+ samples (3 mRNAs). 
(n = 2 mice for P301S; n = 5 mice for P301S hTREM2R47H/+). 
g, Weighted gene co-expression network analysis (WGCNA) of bulk RNA-sequencing data 
from (e) and 8–9-month-old female P301S hTREM2WT/+ mice and line-specific female P301S 
controls. Significant modules are colored. White bars denote non-significant modules (n = 5 
mice for P301S hTREM2R47H/+; n = 6 mice for P301S hTREM2WT/+; n = 3 mice for each P301S 
line-specific controls).  
h, Cell-type enrichment analysis for significant WGCNA modules from (g). 
i, Top 5 enriched KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways of genes 
from the brown and cyan WGCNA modules in (g). Colors of the bars represent the WGCNA 
module. 
j, Network analysis using STRING database on genes from the KEGG “cytokine receptor 
interaction” gene set of the brown module. 
Values are mean ± SEM. Behavioral data represent the combination of two behavioral cohorts 
that were run independently.  Sequencing data represent one independent sequencing 
experiment. For all volcano plots, the cut-offs used were p<0.05 with the Benjamini-Hochberg 
correction and log-2-fold change (log2FC) ≥ 1 or log2FC ≤ -1.  
See also Supplementary Figures 5-7. 
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Figure 3.4 R47H-hTREM2 Increases the Disease-associated Microglia Signature in 
Female Tauopathy Mice. 
a, t-SNE plot of all 1,424 microglial cells analyzed and clustered. (n = 2 mice/genotype, 8-
month-old female mice).  
b, t-SNE plots based on clustering from (a) split by genotype. 
c, Ratio of cells in each cluster by genotype. ****p<0.0001, two-sided Fisher’s exact test. 
d, Volcano plot of DEGs defining cluster 2 compared to cluster 1. 
e, Feature plots of transcript expression overlaid onto t-SNE of all microglial cells. 
f, Correlation scatterplot of DEGs in cluster 2 vs. cluster 1 (x-axis) compared to disease-
associated microglia (DAM) vs. homeostatic microglia (y-axis)40. R2 = 0.7908, ****p < 2.2e-16. 
g-h, RNA in situ (RNAscope) showing Apoe, C1qa, and DAPI signal in the dentate gyrus for 
P301S (g) and P301S hTREM2R47H/+ (h) mice. Dashed square denotes location of insets. 
Arrows denote co-localization of Apoe+ and C1qa+ puncta. 
i, Quantification of percentage of Apoe+ C1qa+ cells, normalized to total number of C1qa+ 
cells from (g-h). *p<0.05 n=3 mice/genotype, 10-11-month-old female mice.  
See also Supplementary Figure 8. 
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Figure 3.5 Microglial R47h-hTREM2 Induces Unique Transcriptional States in Neurons 
and Oligodendrocytes in Female Tauopathy Mice 
a, t-SNE plots of all single nuclei and their annotated cell types from 2 each of P301S and 
P301S hTREM2R47H/+ 9-month-old female mice. 
b, t-SNE plot split by genotype. 
c, Proportion of each cell type for each genotype. 
d, Total number of DEGs for each cell type for P301S hTREM2R47H/+ vs. P301S. FDR < 0.05. 
e-g, Ingenuity pathway analysis’s predicted upstream regulators for oligodendrocytes (e), 
excitatory neurons (f), and inhibitory neurons (g). Red and blue denote upstream regulators 
that are predicted to be activated or inhibited, respectively.   
h, Ingenuity canonical pathway enrichment analysis of DEGs in P301S hTREM2R47H/+ vs. 
P301S by specified cell type. 
See also Supplementary Figure 9.	
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Figure 3.6 R47H-hTREM2 in Human and Mouse is Associated with Mitochondrial 
Changes in Oligodendrocytes 
a, Schematic showing the sex and genotypes of age-matched human donors used for single-
nuclei RNA-sequencing. n = 11,1185 cells from 3 control, 3 AD, and 3 R47H-AD patients; 
102,702 cells were used for downstream analysis. Red and turquoise cartoons denote females 
and males, respectively. For each donor, a sample of brain tissue was obtained from both the 
temporal and frontal cortices. See also Supplementary Table 6. 
b, t-SNE plots of all single nuclei and their annotated cell types from 3 control, 3 AD, and 3 
R47H-AD donors plotted by genotype. 
c, Number of DEGs between R47H-AD vs. AD samples for each cell type. FDR<0.05 
d, Number of overlapping DEGs between R47H-AD vs. AD human and P301S-R47H vs. P301S 
mouse samples for glial cell types. FDR<0.05 
e, Ingenuity canonical pathway enrichment analysis of overlapping upregulated oligodendrocyte 
DEGs found in (d). 
f, Diagram of genes in the oxidative phosphorylation pathway found in (e), with red 
compartments representing upregulation in R47H human and mouse samples.  
Data represent one independent sequencing experiment. See also Supplementary Figure 10. 
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3.9 Supplementary Figures 
	
Supplementary Figure 3.1 R47H-hTREM2 Induces Spatial Learning and Memory 
Deficits in Female Mice (Related to Figure 1) 
Morris water maze assessment of spatial learning and memory in 7–9-month-old 
hTREM2R47H/+ hTREM2WT/+ mice and littermate controls.  
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a-b, Latency to reach the platform during hidden trials (d1–d7) for hTREM2R47H/+ males (a) 
and females (b) and their littermate sex-matched mTrem2+/+ controls. Female hTREM2R47H/+ 
mice exhibited greater latency to reach the platform than littermate controls, indicating 
impaired spatial learning. ****p=0.000, STATA mixed-effects modeling. 
c-d, Cumulative search errors during the 24-hr probe trial for hTREM2R47H/+ males (c) and 
females (d) and their littermate sex-matched mTrem2+/+ controls. Female hTREM2R47H/+mice 
had a significantly greater cumulative search error, suggesting impaired spatial memory. * 
U=13, p=0.0204, Two-tailed Mann-Whitney U-test of area under the curve. 
e-f, Percentage of time spent in the target (T) or the average time spent in the nontarget (N) 
quadrants during the 24-hr probe trial for hTREM2R47H/+ males (e) and females (f) and their 
littermate sex-matched mTrem2+/+ controls. Neither male nor female hTREM2R47H/+ spent 
significantly more time in the target quadrant compared to the nontarget quadrant, indicating 
impaired spatial memory. ***t=6.088, p=0.0001, ****t=7.834, p=5.077e-005, paired two-tailed 
Student’s t-test for n>8, two-tailed Wilcoxon test for n<8. 
g-h, Latency to reach the platform during hidden platform trials (d1–d7) for hTREM2WT/+ 
males (g) and females (h) and their littermate sex-matched mTrem2+/+ controls did not differ. 
STATA mixed-effects modeling. 
i-j, Cumulative search errors during the 24-hr probe trial for hTREM2WT/+ males (i) and 
females (j) and their littermate sex-matched mTrem2+/+ controls were similar. Two-tailed 
Mann-Whitney U-test of area under the curve. 
k-l, Percentage of time spent in the target (T) or the average time spent in the nontarget (N) 
quadrants during the 24-hr probe for hTREM2WT/+ males (k) and females (l) and their 
littermate sex-matched mTrem2+/+ controls. All groups spent significantly more time in the 
target quadrant. *W=-28, p=0.01563 (l), **t=4.810, p=0.001943, ***t=5.752, p=0.0002, 
****t=7.503, p=7.208e-006, paired two-tailed Student’s t-test for n>8, two-tailed Wilcoxon test 
for n<8. 
Values are mean ± SEM.	
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Supplementary Figure 3.2 Neither Human WT nor R47H hTREM2 Affect Overall Activity or 
Anxiety Levels (Related to Figure 1) 
a-d, Open-field assessment of overall activity of 7–9-month-old hTREM2WT/+ male (a) and 
female (b) mice and hTREM2R47H/+ male (c) and female (d) mice and their littermate mTrem2+/+ 
controls. Total activity was similar across all groups. Two-tailed Student’s t-test for n>8, two-
tailed Mann-Whitney U-test for n<8. 
e-h, Elevated plus maze assessment of anxiety levels in 7–9-month-old hTREM2WT/+ male (e) 
and female (f) mice and hTREM2R47H/+ male (g) and female (h) mice and littermate mTrem2+/+ 
controls. All groups spent a similar percentage of time in the open arms. Two-tailed Student’s t-
test for n>8, two-tailed Mann-Whitney U-test for n<8.  
Values are mean ± SEM.		
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Supplementary Figure 3.3 Quality Control Assessment of Single-nuclei RNA-
sequencing (Related to Figure 2) 
a-b, Quality control metrics of cell size, coverage, correlation between mitochondrial RNA and 
total genes detected, and correlation between genes and total genes (UMI) detected for each 
sample. Single nuclei were isolated from 9–month-old female mTrem2+/+and hTREM2R47H/+ 
mouse hippocampal tissue for 10x Genomics single-nuclei sequencing. 31,783 cells were 
used for downstream analysis. (n = 2 mice/genotype). 
c, Violin plots showing spread of total genes, total molecules detected, and percent of 
mitochondrial RNA. 
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Supplementary Figure 3.4 R47H-hTREM2 Does Not Affect Microglial Morphology, 
Density, or Motility (Related to Figure 2) 
Immunohistochemical analysis of 8–9-month-old mice. Circles in bar graphs represent data 
from one mouse, acquired by averaging all sections (8–10 per mouse) or microglia (~11 
cells/mouse) traced for that mouse. For comparisons, data from hTREM2WT/+ and 
hTREM2R47H/+ mice were normalized to data from line-specific mTrem2+/+ controls.  
a, Representative images of Iba1 staining in the hippocampus. 
b, Percentage of hippocampal area positive for Iba1. Entire hippocampus was quantified. 
Two-tailed Student’s t-test. 
c, Representative images of Iba1 staining in the cortex. 
d, Percentage of cortical area positive for Iba1. Entire cortex was quantified. Two-tailed 
Student’s t-test. 
e, Representative images of Iba1 staining and Imaris 3D reconstruction of microglia in the 
CA3 hippocampal region. 
f-g, Imaris quantification of total process length per cell (f) and number of branch points per 
cell for each genotype (g). Two-tailed student’s t-test. 
h, Quantification of microglial process velocity in 12-17-month-old mice during 10 min of 
baseline recordings (n = 5 mTrem2+/+, n = 3 hTREM2WT/+, n = 6 hTREM2R47H/+ mice, ~25 
processes/mouse). One-way ANOVA. 
i, Representative images at 0, 18, 36, and 57 minutes after laser-induced injury. Red circle 
indicates region of injury. 
j, Quantification of the normalized microglial response to focal laser-induced tissue injury for 
60 min after injury.  (n = 6 mTrem2+/+, n = 5 hTREM2WT/+, n = 6 hTREM2R47H/+ mice). STATA 
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mixed-effects modeling. 
Scale bars: hippocampus, 300 µm; cortex, 200 µm; hippocampal microglia, 20 µm, ablation, 
15 µm.  
Values are mean ± SEM. All data are from one independent experiment, unless otherwise 
noted. See also Supplementary Movie 1. 
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Supplementary Figure 3.5 WT-hTREM2 Phenocopies Mouse Trem2 in Tauopathy Mice 
(Related to Figure 3)  
a-d, Latency to reach the platform during hidden trials (d1-d7) and cumulative search errors 
during the 72-hr probe trial did not differ significantly between male (a,c) and female (b,d) 
P301S and P301S hTREM2WT/+ mice. A representative search track is shown for each 
genotype. The black square indicates the platform location in the upper left quadrant. The four 
quadrants of the pool are delineated by dashed lines. STATA mixed-effects modeling for a,b. 
Two-tailed Mann-Whitney U-test of area under the curve for c,d. 
Values are mean ± SEM.	
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Supplementary Figure 3.6 Neither WT nor R47H hTREM2 Affect Overall Activity or 
Anxiety Levels in Tauopathy Mice (Related to Figure 3) 
a-d, Open-field assessment of overall activity of 7–9-month-old P301S hTREM2WT/+ male (a) 
and female (b) and P301S hTREM2R47H/+ male (c) and female (d) mice and littermate P301S 
controls. Total activity was similar across all groups. Two-tailed Student’s t-test for n>8, two-
tailed Mann-Whitney U-test for n<8. 
e-h, Elevated plus maze assessment of anxiety levels in 7–9-month-old hTREM2WT/+ male (e) 
and female (f) mice and hTREM2R47H/+ male (g) and female (h) mice and littermate P301S 
controls. All groups spent a similar percentage of time in the open arms. Two-tailed Student’s t-
test for n>8, two-tailed Mann-Whitney U-test for n<8. 
Values are mean ± SEM.	
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Supplementary Figure 3.7 R47H-hTREM2 Has Sex-Dependent Effects on Tau Load and 
Microgliosis in Tauopathy Mice (Related to Figure 3) 
Immunohistochemical analysis of 8–9-month-old mice. In bar graphs, points represent the 
average of 8–10 sections per mouse, unless otherwise noted. Values are normalized to line-
specific, sex-matched P301S mTrem2+/+ littermate controls.  
a and j, Representative images of MC1 immunostaining in the hippocampus and entorhinal 
cortex of male (a) and female (j) mice. 
b,c,k,l, Percentage of MC1+ area in male hippocampus (b) and cortex (c) and female 
hippocampus (k) and cortex (l) of P301S hTREM2WT/+ and P301S hTREM2R47H/+ mice. Entire 
hippocampus and entire cortex were quantified. Two-tailed Mann-Whitney U-test. 
d and m, Representative images of Iba1 immunostaining in the hippocampus and entorhinal 
cortex of male (d) and female (m) mice. 
e,f,n,o, Percentage of Iba1+ area in male hippocampus (e) and cortex (f) and female 
hippocampus (n) and cortex (o) of P301S hTREM2WT/+ and P301S hTREM2R47H/+ mice. The 
percentage of Iba1+ area was significantly reduced in female P301S hTREM2R47H/+ mice. Entire 
hippocampus and entire cortex were quantified. *U=4, p=0.0140, two-tailed Mann-Whitney U-
test. 
g and p, Representative Iba1 staining of CA3 hippocampal microglial cells and Imaris 3D 
reconstruction in males (g) and females (p) of P301S hTREM2WT/+ and P301S hTREM2R47H/+ 
mice. 
h,i,q,r, Imaris-based automatic quantification of total process length per cell in male (h) and 
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female (q) P301S hTREM2WT/+ and P301S hTREM2R47H/+ mice and number of branch points per 
cell in male (i) and female (r) mice of those two genotypes. Microglia from male P301S 
hTREM2R47H/+ had significantly longer processes (h) and more branch points (i) than controls. ** 
p = 0.0015, t = 6.097 (h), ** p = 0.0023, t = 5.064 (i), two-tailed, unpaired t-test with Welch’s 
correction. Puncta represent the average of ~11 microglia/mouse. Scale bars: hippocampus, 
300 µm; cortex, 200 µm; hippocampal microglia, 20 µm.  
Values are mean ± SEM. Data represent the combination of two independent experiments. 
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Supplementary Figure 3.8 Deep Single-Cell RNA-Sequencing of Microglia from Mouse 
Hippocampal Tissue (Related to Figure 4) 
a, FACs gating strategy for microglia sorting. 
b, Distributions for different quality control metrics.   
c, Correlation between number of reads and number of genes detected, used to identify final 
1424 cells used for analysis. 
d, Table denoting for each sample, the number of cells sequenced and number of cells that 
passed quality control and were included in the final analysis.	 
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Supplementary Figure 3.9 Quality Control Assessment of Single-nuclei RNA-
sequencing from Tauopathy Mouse Hippocampal Tissue (Related to Figure 5) 
a-b, Quality control metrics of cell size, coverage, correlation between mitochondrial RNA and 
total genes detected, and correlation between genes and total genes (UMI) detected for each 
sample. Single nuclei were isolated from 9–month-old female P301S and P301S 
hTREM2R47H/+ mouse hippocampal tissue for 10x Genomics single-nuclei sequencing. 31,783 
cells were used for downstream analysis. (n = 2 mice/genotype). 
c, Violin plots showing spread of total genes, total molecules detected, and percent of 
mitochondrial RNA. 
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Supplementary Figure 3.10 Single-Nuclei RNA-Sequencing of Human Cortical Tissue 
(Related to Figure 6) 
a, Violin plots of quality control metrics for sequencing. 
b, Correlation scatterplot of quality control metrics for sequencing. 
c, Overrepresentation analysis between cluster marker genes identified for each cell type in 
this dataset (rows) and published marker genes (columns) (Lake et al. 2018, Wang et al. 
2018) (PsychENCODE).  p-values have been adjusted for multiple hypothesis testing (-log10 
(Bonferroni corrected p values) are shown). 
d, Feature plots showing expression of cell type marker genes for each cell type. 
e, t-SNE plot of all single nuclei and their annotated cell types (n = 102,702 cells) from 3 
control, 3 AD and 3 R47H-AD donors 
f, t-SNE plot of all single nuclei and their brain region locations.  
g, t-SNE plots of single nuclei showing cells from each donor (red) overlaid on all cells 
analyzed (gray). 
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3.10 Legend for Supplementary Movie	
	
Supplementary Movie 3.1 R47H-hTREM2 Does Not Affect Microglial Response to Injury 
(Related to Figure 2) 
Video file of microglial responses of 12-17-month-old Cx3cr1GFP/+ mTrem2+/+, hTREM2WT/+, and 
hTREM2R47H/+ mice to an acute laser-induced injury in vivo over a 60-min time period, played 
one after the other. Scale bar: 15 µm. 
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Chapter 4: Discussion and Future Directions 
	
4.1 Questions Remaining about Basic Trem2 Biology 
 Despite 6 years of research since the identification of the R47H AD-risk variant, little is 
known about Trem2 biology in the brain and how it is altered by the R47H variant. The field has 
been plagued by contradictory findings in different mouse models and many unresolved 
puzzles. While studies have attempted to address some of the contradictions (i.e. by proposing 
that Trem2’s effects on pathology are time-sensitive), many observations remain a mystery. 
 Several questions about basic Trem2 biology are unresolved. These include Trem2’s 
spatial localization in the brain, whether Trem2 levels are developmentally regulated, and its 
heterogeneous expression in microglial populations in the healthy brain. Studies in human and 
mouse tissue suggest that Trem2 is differentially expressed across the brain, with the highest 
Trem2 expression predominantly in the white matter and basal ganglia24,34,35. Why is Trem2 
upregulated in these regions? Trem2 binds components of myelin41. Does its upregulation in the 
white matter pertain to the high density of myelin in this region? Despite its abundant expression 
in the basal ganglia, we have yet to understand the consequences of Trem2 deficiency on this 
brain region. In the context of pathology, studies have found region-specific effects of Trem2 on 
amyloid pathology33,41,51. Are these region-specific effects due to Trem2’s putative regional 
distribution in the parenchyma, rendering certain areas more sensitive to low Trem2 levels? 
More careful characterizations of Trem2 expression in the brain throughout the lifespan of a 
mouse and human in health and disease are needed to solidify Trem2’s spatial localization and 
the consequences of this regional specificity on brain function.   
  Trem2 appears to be developmentally downregulated, such that Trem2 is barely 
detectable at baseline in the healthy mouse brain30,31,35. Moreover, only small subset of 
microglia expresses Trem2 at baseline31. What are the roles of these rare Trem2+ microglia in 
the healthy brain and where are they located? What is the signal that increases microglial 
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Trem2 expression during disease? Through transcriptomic and proteomic studies of these 
Trem2+ microglia in the healthy brain, particularly in the human brain, we may unravel key 
Trem2 functions during homeostasis that could serve as therapeutic targets. Moreover, we can 
identify transcripts and signaling pathways that regulate Trem2 and that are regulated by 
Trem2, which would improve our understanding of Trem2 biology and how it regulates 
chemotaxis, cell survival, proliferation, phagocytosis, inflammation, and synapse pruning in the 
brain.  
 
4.2 Questions Remaining about Trem2 Biology in the Context of Alzheimer’s Disease  
 In addition to understanding these fundamental aspects of Trem2 biology, unraveling the 
ramifications of Trem2-deficient and Trem2-mutant microglia in disease models is also needed 
to advance our understanding of Trem2 biology. Given the low levels of Trem2 expression in the 
healthy brain, it may be challenging to uncover its function without presenting the brain with a 
challenge that relies on Trem2 signaling. Yet, we were able to observe synaptic and behavioral 
deficits in heterozygous R47H-hTREM2 mice in the absence of any other genetic manipulations 
or challenges. These findings indicate that this mutation is detrimental enough on its own over 
time, despite the reported low baseline levels of Trem2 expression in microglia. Moreover, they 
highlight the importance of this gene such that a single amino acid mutation in its ligand-binding 
domain causes global non-cell autonomous effects, ultimately resulting in cognitive deficits.  
Trem2 deficiency reduces microgliosis and protects again tau-induced degeneration, 
while increasing amyloid-associated neurite toxicity41,46,51,55,61,70,82,84. Does Trem2 indeed have 
opposing effects on tau and amyloid load? Do these opposing effects result in opposing 
functional outcomes, i.e. cognitive deficits? Future studies looking at the consequences of 
Trem2 deficiency and R47H-Trem2 at multiple time points throughout disease progression could 
address the prevailing hypothesis that Trem2’s differential effects on tau and amyloid are due to 
the different times at which these pathologies arise. In addition, studies aimed at unraveling the 
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effects of Trem2 in a mouse model that expresses both amyloid and tau pathology may help 
shed light on what occurs in AD patients who have both forms of protein aggregates. Would 
Trem2 preferentially exacerbate the accumulation of one aggregate over the other, or would it 
affect both aggregates the same way, or show no effect on aggregate load? More importantly, 
what would the functional consequences be? Very few studies have utilized functional assays 
and have instead relied on tau or amyloid load as a proxy for toxicity. However, protein 
aggregates may not reflect actual toxicity. In Huntington’s disease, for example, neuronal 
inclusions are considered a protective mechanism – a way for neurons to sequester protein 
aggregates to reduce their toxicity85. In tauopathy mice, Trem2 deficiency protects against 
cortical degeneration, but has no effect on tau load46,61, demonstrating a disconnect between 
tau burden and toxicity. Thus, future studies should incorporate functional readouts, such as 
survival curves, electrophysiology, and behavior, to directly interrogate the pathogenicity of 
Trem2 deficiency in amyloid and tau models.  
 Based on work presented in chapter three, understanding how Trem2 regulates 
crosstalk between microglia, oligodendrocytes, and neurons may shed light on R47H’s toxicity. 
Are microglia communicating directly to oligodendrocytes, neurons, or both? sTREM2 staining is 
found on neurons26,33, and is reduced in the R47H-TREM2 mice33, suggesting that Trem2 may 
signal to neurons directly and that this signaling is likely disrupted in R47H-TREM2 mice. 
Neuronal binding of sTREM2 may be because the neurons are unhealthy and therefore have 
exposed phosphatidylserine on the cell surface, which is a known ligand for Trem2. However, 
the nuclei of sTrem2+ neurons appear healthy33, suggesting that neurons express an unknown 
sTrem2 receptor. Future studies aimed at more carefully characterizing the health of sTrem2+ 
neurons and identifying potential sTrem2 receptors on neurons will be key. Furthermore, it is 
unclear why R47H-hTREM2 binds poorly to neurons. Overall TREM2 levels are similar between 
wild-type and R47H-hTREM2, indicating that similar amounts of TREM2 are available to be 
shed. Moreover, it is shed as effectively as wild-type human TREM2 in vitro33, but perhaps 
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shedding is impaired in vivo. It may be that mutant sTREM2 binds more weakly to neurons, and 
therefore less mutant sTREM2 is present on neurons at a single point in time. Or perhaps it 
binds just as effectively as wild-type hTREM2, but is degraded faster. This striking observation 
will require further work to unravel.   
Trem2-regulated microglial communication with other cell types may occur through other 
signaling molecules aside from sTrem2. Characterizing the microglia secretome (molecules 
released by microglia to communicate with their surroundings) in wild-type, Trem2-deficient, and 
R47H-hTREM2 mice may help to identify how this crosstalk is occurring, and how the 
secretome is modified by the R47H variant. Moreover, transcriptomic profiling sTrem2+ and 
sTrem2- neurons may help us understand how sTrem2 affects neuronal function beyond its role 
in synapse pruning during development58,59, and may shed light on the increased synaptic 
transmission we observed in the R47h-hTREM2 mice. As Trem2 is part of the microglial 
sensome (microglial molecules used to detect endogenous ligands and microbes)28, it may 
impact expression of other microglial sensome markers through its downstream signaling 
cascades. Profiling the microglial sensome in Trem2-deficient and R47H-Trem2 microglia can 
highlight Trem2-regulated pathways in microglia that are dysregulated in R47H-carriers.    
 Microglia, as the phagocytes of the brain, take up myelin debris and secrete factors that 
promote differentiation of oligodendrocyte precursor cells (OPCs) and subsequent migration to 
the site of injury and remyelination45. Studies suggest that Trem2 is important for myelin cleanup 
and remyelination45,86. Yet, the underlying signaling mechanisms are unknown. Moreover, it is 
unclear whether Trem2 can regulate OPC differentiation or migration, which could also 
contribute to exacerbated disease progression in Trem2-deficient mouse models of 
demyelination.  
 The R47H variant is purported to be a partial loss-of-function mutation33,36,37,40,42,44,78. 
This hypothesis is primarily based off of R47H-Trem2’s impairment in ligand-binding. Moreover, 
these studies compared R47H-overexpressing microglia to Trem2-deficient microglia, when it is 
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R47H heterozygosity that increases risk for AD. Thus, studies are needed to determine whether 
R47H is simply a loss-of-function, or whether it may also exhibit gain-of-function phenotypes 
such as binding to ectopic ligands or increased downstream signaling. Preliminary work from 
our R47H-hTREM2 and WT-hTREM2 mice suggests that R47H-hTREM2 microglia increase 
expression of the disease-associated microglia (DAM) signature, which is downregulated in 
Trem2-deficient microglia62. This finding suggests a gain-of-function effect of the mutation with 
respect to DAM genes. To more accurately determine whether R47H causes gain-of-function 
effects, phosphoproteomics of R47H heterozygous microglia and Trem2-haploinsufficient 
microglia could identify whether any signaling pathways that are downregulated in Trem2-
haploinsufficient microglia are upregulated in R47H-hTREM2.  
 Like R47H-TREM2, ApoE4 is also a single amino acid change compared to its 
counterpart ApoE3, which is not a risk factor for AD. The TREM2 field may benefit from 
observing how the ApoE4 field identified its pathogenicity. One important note that has not been 
addressed in the field is the presence of Trem3. In humans, Trem3 is a pseudogene. However, 
in mice, Trem3 is functional. In the periphery, it associates with Dap12 and promotes 
macrophage activation87. Its function in the brain is unknown. If Trem3 phenocopies Trem2, 
then this redundancy may explain why Trem2 knockout mice do not recapitulate hallmarks of 
Nasu-Hakola disease, even at old age45. A better understanding of Trem3 function may be 
required to determine whether we need to remove Trem3 from mouse models in order to 
unmask hidden phenotypes in Trem2-deficient or Trem2-mutant microglia.  
 Lastly, the field has been slowed down by the use of different mutant and knockout 
Trem2 mouse models that were recently found to exhibit different artifacts from the way the 
lines were generated (i.e. the cryptic splice site in R47H mouse Trem283, or significant 
upregulation of Trem-like genes88). These artifacts likely, in part, contribute to the contradictory 
findings related to Trem2’s roles in health and disease. The field may benefit from focusing its 
efforts on the mouse model that most closely mimics the human condition. To do this, more 
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research is needed on Trem2 expression and function in both healthy and diseased human 
brain tissue. Once the field adopts a consistent mouse model, reproducibility will hopefully 
increase and we will unravel more key insights into Trem2 function and dysfunction, and 
consequently microglia function and dysfunction, in health and disease.  
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Chapter 5: Conclusion 
 
R47H-TREM2 increases risk for AD and several neurodegenerative diseases, but it does 
not cause any of them. Indeed, causal mutations for Nasu-Hakola disease that result in 
complete lack of Trem2 exhibit dramatic phenotypes, creating non-functional or truncated 
proteins that fail to mature and reach the cell surface. R47H-TREM2, on the other hand, is able 
to mature normally and be expressed at the cell surface. This suggests that R47H-TREM2’s 
toxic effects in the brain may be small, but as the toxicity accumulates in the brain over many 
decades, it may tip the brain into a state of vulnerability for disease. Thus, unraveling the 
mystery behind this risk variant’s strong association with AD may require aging for the 
accumulated deficits to manifest in a mouse, or challenges to speed up the process of 
accumulation and uncover deficits earlier on. Overall, the most promising findings in the field so 
far implicate Trem2 in lipid sensing, plaque compaction, and allowing microglia to shift from 
homeostatic to reactive in response to stimuli. Our work highlights the importance of studying 
Trem2 haploinsufficient mice, as they do not always phenocopy Trem2 deficient mice – 
potentially due to compensation from Trem3 or other microglial genes. Our work also shows that 
R47H-hTREM2 is sufficient to cause synaptic and cognitive abnormalities along with significant 
transcriptional changes in neurons and oligodendrocytes that may underlie these deficits.  
This is just the beginning. The better we understand this key microglial gene with 
pleiotropic functions, the more insight we will have into the ways in which microglial dysfunction 
exacerbates disease pathogenesis. Future work profiling the brains of R47H-AD carriers will be 
critical in order to identify dysregulated pathways to focus on. These pathways can then be 
dissected mechanistically using animal models and used to identify therapeutic targets not only 
for R47H-carriers, but for AD patients in general.  
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